[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2629
1. Botelho CH, Magalhães AV, Mello PA, Schmitt FC, Casulari LA: Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr; 2006 Mar;64(1):60-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas.
  • The subcellular events implicated on the formation and behavior of pituitary adenomas are not fully understood.
  • In this study we investigated the presence of p53, Ki-67 and c-erb B2 in 38 pituitary adenomas with immunohistochemical positivity for GH and prolactin (n=26; 68.4%), for prolactin (n=9; 23.7%) and for GH (n=3. 7.8%).
  • [MeSH-major] Growth Hormone / secretion. Ki-67 Antigen / analysis. Neoplasm Proteins / analysis. Pituitary Neoplasms / metabolism. Prolactinoma / metabolism. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622555.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 9002-72-6 / Growth Hormone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


2. Bakar B, Hakki Tekkok I: Streptococcus pneumoniae meningo-encephalitis after trans-sphenoidal surgery: a case report. Acta Chir Belg; 2009 Oct;109(5):641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningismus or meningitis are known to occur after pituitary surgery; meningo-encephalitis caused by Streptococcus pneumoniae following a trans-sphenoidal approach has not been previously reported.
  • [MeSH-major] Adenoma / surgery. Meningoencephalitis / microbiology. Pituitary Neoplasms / surgery
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Pneumococcal Infections. Postoperative Complications / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994813.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


3. Su DH, Liao KM, Chen HW, Chang TC: Long-term primary medical therapy with somatostatin analogs in acromegaly. J Formos Med Assoc; 2006 Aug;105(8):664-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1 was a 54-year-old man with a pituitary macroadenoma.
  • Case 2 was a 60-year-old woman with a 1.3 cm pituitary tumor.
  • She had received bilateral total hip replacement for hip osteoarthritis at the age of 59 years.
  • These cases illustrate that long-term treatment with somatostatin analogs offers an alternative choice in selected acromegalic patients, such as those with pituitary tumor who cannot be cured by surgery, those who have unacceptable anesthetic risk and those who refuse surgery.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935768.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


Advertisement
4. Ahmed IM, Kannappan H, Datta-Chaudhuri M, Rauf O: Hypopituitarism due to pituitary macroadenoma in an older person: an unusual presentation. J Am Geriatr Soc; 2008 Jan;56(1):172-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism due to pituitary macroadenoma in an older person: an unusual presentation.
  • [MeSH-major] Adenoma / complications. Hypopituitarism / etiology. Pituitary Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Follow-Up Studies. Hormone Replacement Therapy / methods. Humans. Inappropriate ADH Syndrome / blood. Inappropriate ADH Syndrome / diagnosis. Magnetic Resonance Imaging. Male. Pituitary Hormones / blood. Severity of Illness Index. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Geriatr Soc. 2008 Jul;56(7):1377 [18774982.001]
  • (PMID = 18184211.001).
  • [ISSN] 1532-5415
  • [Journal-full-title] Journal of the American Geriatrics Society
  • [ISO-abbreviation] J Am Geriatr Soc
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


5. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW: Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab; 2009 Jun;94(6):1853-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The least prevalent conditions, affecting less than 1% of the U.S. population, were diabetes mellitus in children and pituitary adenoma.
  • Conditions with the lowest incidence were adrenocortical carcinoma, pheochromocytoma, and pituitary adenomas.
  • Sparse data were available on pituitary, adrenal, and gonadal disorders.
  • [MeSH-major] Endocrine System Diseases / epidemiology. Metabolic Diseases / epidemiology

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • MedlinePlus Health Information. consumer health - Metabolic Disorders.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] Diabetes. 2002 Oct;51(10):3120-7 [12351457.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-97-101 [16315387.001]
  • [Cites] J Pediatr. 1990 Mar;116(3):450-5 [2137877.001]
  • [Cites] Am J Public Health. 2005 Sep;95(9):1536-9 [16051928.001]
  • [Cites] Arch Intern Med. 2006 Jan 23;166(2):207-12 [16432090.001]
  • [Cites] Neurology. 1993 Apr;43(4):817-24 [8469345.001]
  • [Cites] Expert Opin Pharmacother. 2007 Apr;8(6):787-95 [17425474.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] JAMA. 2000 May 3;283(17):2253-9 [10807384.001]
  • [Cites] JAMA. 1978 Feb 20;239(8):742-4 [579637.001]
  • [Cites] JAMA. 2007 Jun 27;297(24):2716-24 [17595272.001]
  • [Cites] Pediatrics. 2006 Oct;118(4):1510-8 [17015542.001]
  • [Cites] Radiology. 1997 Jan;202(1):41-6 [8988190.001]
  • [Cites] Diabetes Care. 2000 Apr;23(4):465-71 [10857936.001]
  • [Cites] J Diabetes Complications. 2000 Jan-Feb;14(1):1-6 [10925059.001]
  • [Cites] Bone. 2000 Sep;27(3):423-7 [10962355.001]
  • [Cites] Pediatrics. 2005 Nov;116(5):1122-6 [16263998.001]
  • [Cites] Diabetes Care. 2001 Jul;24(7):1204-9 [11423503.001]
  • [Cites] Steroids. 2008 Dec 12;73(13):1345-52 [18579171.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2008 Jul 18;57(28):765-8 [18636063.001]
  • [Cites] Diabetes Care. 2007 Jun;30(6):1562-6 [17372155.001]
  • [Cites] Steroids. 2008 Dec 12;73(13):1311-7 [18687348.001]
  • [Cites] Arch Intern Med. 1987 Feb;147(2):221-4 [3492979.001]
  • [Cites] Ann Intern Med. 2003 Aug 5;139(3):161-8 [12899583.001]
  • [Cites] Kidney Int. 2003 May;63(5):1817-23 [12675858.001]
  • [Cites] Am J Ophthalmol. 1995 Oct;120(4):511-7 [7573310.001]
  • [Cites] Int J Clin Pract. 2008 May;62(5):791-8 [18266714.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):489-99 [11836274.001]
  • [Cites] Am J Med. 1991 Oct;91(4):363-70 [1951380.001]
  • [Cites] Diabetes Care. 2003 Mar;26(3):645-9 [12610015.001]
  • [Cites] Diabetes Care. 2001 Jun;24(6):1029-32 [11375365.001]
  • [Cites] Obstet Gynecol. 2004 Mar;103(3):526-33 [14990417.001]
  • [Cites] Ophthalmology. 2004 Jul;111(7):1298-306 [15234129.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2008 Oct 31;57(43):1169-73 [18971918.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):29-35 [8021781.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 Oct 15;53(40):941-4 [15483527.001]
  • [Cites] Mayo Clin Proc. 1983 Dec;58(12):802-4 [6645626.001]
  • [Cites] Am J Epidemiol. 2006 Nov 1;164(9):873-80 [16905646.001]
  • [Cites] Am J Med. 2007 Oct;120(10):911.e9-15 [17904464.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9 [15181052.001]
  • [Cites] JAMA. 2005 Apr 20;293(15):1868-74 [15840861.001]
  • [Cites] J Bone Miner Res. 2000 Mar;15(3):461-5 [10750560.001]
  • [Cites] J Bone Miner Res. 2006 Jan;21(1):171-7 [16355286.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Mayo Clin Proc. 1970 May;45(5):396-404 [5443236.001]
  • [Cites] Diabetes Care. 2006 Jun;29(6):1263-8 [16732006.001]
  • [Cites] J Urol. 2000 Feb;163(2):460-3 [10647654.001]
  • [Cites] Arch Intern Med. 2005 Jul 25;165(14):1606-11 [16043678.001]
  • [Cites] Diabetes Care. 2008 Mar;31(3):587-9 [18071007.001]
  • [Cites] J Bone Miner Res. 1997 Nov;12 (11):1761-8 [9383679.001]
  • [Cites] World J Surg. 2006 May;30(5):872-8 [16680602.001]
  • [Cites] Diabetes Care. 2006 Aug;29(8):1902-8 [16873800.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Nov 10;55(44):1201-3 [17093386.001]
  • [Cites] Am J Ophthalmol. 2006 Mar;141(3):446-455 [16490489.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Diabetes Care. 2001 Aug;24(8):1508-9 [11473103.001]
  • [Cites] WMJ. 2005 Nov;104(8):59-65 [16425924.001]
  • [Cites] Diabetes Care. 1993 Jan;16(1):354-6 [8422809.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):226-34 [17940444.001]
  • [Cites] Diabetes Care. 2005 Nov;28(11):2745-9 [16249550.001]
  • [Cites] Diabetes Care. 2008 May;31(5):899-904 [18223030.001]
  • [Cites] Mayo Clin Proc. 2005 Jun;80(6):753-8 [15948298.001]
  • [Cites] Steroids. 2008 Dec 12;73(13):1333-8 [18565562.001]
  • [Cites] Diabetes Care. 2001 Jun;24(6):1053-9 [11375370.001]
  • [Cites] Diabetes Care. 2005 Mar;28(3):579-84 [15735191.001]
  • [Cites] J Community Health. 2006 Feb;31(1):7-23 [16482763.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Nov 4;54(43):1097-100 [16267496.001]
  • [Cites] J Pediatr. 1990 Feb;116(2):278-80 [2299502.001]
  • [Cites] JAMA. 2001 Dec 12;286(22):2815-22 [11735756.001]
  • [Cites] Arch Intern Med. 2004 Apr 26;164(8):885-91 [15111375.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):1979-87 [12727941.001]
  • [Cites] Diabetes. 2007 Dec;56(12):2990-6 [17898128.001]
  • [Cites] Circulation. 2006 Jun 27;113(25):2914-8 [16785337.001]
  • [Cites] Diabetes. 1987 Jun;36(6):721-9 [3569671.001]
  • [Cites] Am J Epidemiol. 1981 Nov;114(5):697-704 [7304597.001]
  • (PMID = 19494161.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK079637
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


6. Tokumaru AM, Sakata I, Terada H, Kosuda S, Nawashiro H, Yoshii M: Optic nerve hyperintensity on T2-weighted images among patients with pituitary macroadenoma: correlation with visual impairment. AJNR Am J Neuroradiol; 2006 Feb;27(2):250-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic nerve hyperintensity on T2-weighted images among patients with pituitary macroadenoma: correlation with visual impairment.
  • PURPOSE: Visual acuity (VA) disturbance other than field defect is important in evaluating patients with pituitary macroadenoma.
  • The purpose of this study was to evaluate MR imaging appearances of optic nerves in patients with pituitary macroadenoma and to ascertain whether visual impairment was correlated with abnormality in optic nerve signal intensity.
  • PATIENTS AND METHODS: Twenty-seven patients with pituitary macroadenoma were examined.
  • Optic nerves were evaluated on T2-weighted images and correlations of signal intensity abnormality with VA disturbance, visual field disturbance, degree of optic chiasm compression, pathologic findings of surgical specimen, and disease duration were statistically analyzed.
  • Bilateral signal intensity abnormality of the optic nerve was seen in 5 patients.
  • Signal intensity abnormality of the optic nerve was seen at the site of compression and in the ventral side of the tumor.
  • These patients did not demonstrate signal intensity abnormality posterior to the tumor.
  • CONCLUSION: Hyperintensity of the optic nerves ventral to the pituitary macroadenoma was associated with VA impairment.
  • MR imaging of the optic nerves can provide valuable information for management of pituitary macroadenoma.
  • [MeSH-major] Adenoma / diagnosis. Magnetic Resonance Imaging. Optic Nerve / pathology. Pituitary Neoplasms / diagnosis. Vision Disorders / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Nerve Compression Syndromes / diagnosis. Optic Chiasm / pathology. Optic Nerve Diseases / diagnosis. Papilledema / diagnosis. Sensitivity and Specificity. Statistics as Topic. Visual Acuity / physiology. Visual Fields / physiology


7. Wasko R, Jankowska A, Waligorska-Stachura J, Andrusiewicz M, Jaskula M, Sowinski J: Survivin expression in pituitary adenomas. Neuro Endocrinol Lett; 2005 Jun;26(3):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in pituitary adenomas.
  • OBJECTIVES: The aim of our study was to determine the survivin expression in different types of pituitary adenomas.
  • METHODS: Tissue samples were obtained during surgical removal of the tumour from 12 patients with diagnosed: acromegaly in seven cases, non-functioning pituitary tumours in four cases and prolactinoma in one case.
  • RESULTS: In agreement with the current view that survivin is a tumor-associated antigen, highly expressed in various tumours, we found the presence of survivin expression as a characteristic feature of human pituitary adenomas.
  • The findings of our study demonstrated the presence of an active survivin gene in all twelve analysed pituitary tumours.
  • CONCLUSIONS: Based on these findings, we conclude that the estimation of survivin expression in human pituitary tumours may help predict tumour growth and prognosis.
  • [MeSH-major] Adenoma / physiopathology. Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic. Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Pituitary Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990723.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


8. Osa LE, Horjen J, Aanderud S, Lund-Johansen M: [Surgical treatment of hormone-producing pituitary adenomas]. Tidsskr Nor Laegeforen; 2006 May 11;126(10):1330-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of hormone-producing pituitary adenomas].
  • BACKGROUND: Transsphenoidal surgical treatment is established as a treatment of hormonally active pituitary tumours, except prolactinomas.
  • METHODS: We did a retrospective survey evaluating the operative results of one surgeon operating hormonally active pituitary tumours from 1993 through 2002 at Haukeland University Hospital.
  • [MeSH-major] Adenoma / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Clinical Competence. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / adverse effects. Neurosurgical Procedures / methods. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Retrospective Studies. Sphenoid Bone / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691270.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


9. Zhang R, Shen WQ, Zhou LF: [Primary pediatric central nervous system tumors statistic: study of 763 cases in a single institution]. Zhonghua Yi Xue Za Zhi; 2007 Feb 13;87(7):442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 688 of the 763 patients had pathological diagnosis.
  • The most common 5 categories of tumors were: astrocytic tumors (25.7%, 177/688), craniopharyngioma (12.8%, 88/688), medulloblastoma (9.3%, 64/688), germ cell tumors (8.9%, 61/688), and pituitary adenoma (7.5%, 52/688).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459219.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Oliveira RS, Castro Md, Antonini SR, Martinelli CE Jr, Moreira AC, Machado HR: Surgical management of pediatric Cushing's disease: an analysis of 15 consecutive cases at a specialized neurosurgical center. Arq Bras Endocrinol Metabol; 2010 Feb;54(1):17-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS AND METHODS: Retrospective study, in which the medical records, histology and pituitary imaging of 15 consecutive pediatric patients with Cushing's disease (mean age: 13 years) were evaluated by the same team of endocrinologists and a neurosurgeon from 1982 to 2006.
  • Follow-up was for a median time of 11.5 years (range: 2 to 25 years).
  • [MeSH-major] Adenoma / surgery. Hypophysectomy / methods. Pituitary ACTH Hypersecretion / surgery. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414543.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


11. Târcoveanu E, Niculescu D, Cotea E, Moldovanu R, Vasilescu A, Crumpei F, Zbranca E, Zugun F, Rusu V, Ferariu D: [Parathyroid glands involvement in multiple endocrine neoplasia]. Rev Med Chir Soc Med Nat Iasi; 2009 Apr-Jun;113(2):482-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parathyroid gland involvement is usually noted in Multiple Endocrine Neoplasia (MEN) type I and type II.
  • Parathyroid glands tumor associated with endocrine pancreatic tumor, as well as pituitary tumors is the typical pattern of MEN I.
  • The parathyroid gland is the most frequent abnormality in MEN I.
  • In three cases with young ages (28-33 years old) and familial setting, the MEN I syndrome was "complete" (parathyroid adenoma, gastrinoma or insulinoma and pituitary adenoma--prolactinoma or GH-secreting tumors), and, in the other two cases, with 57 and 68 years old respectively, the MEN I syndrome was "incomplete" with parathyroid glands and pituitary gland involvement.
  • Unfortunately one patients died due to severe endocrine disorder.
  • During the necropsy, the pituitary adenoma has been diagnosed.
  • The imagistic and laboratory test diagnosed a tumor situated into the pancreatic body, and an parathyroid adenoma.
  • The resection of pancreatic tumor associated with resection of the parathyroid adenoma, in the same time, were performed.
  • The other two cases with "incomplete" MEN were older then the first patients, and were diagnosed with hyperparathyrodism and pituitary gland tumor.
  • The resection of parathyroid gland adenoma has been performed in both cases, with uneventful postoperative course.
  • There are two kinds of MEN associated with parathyroid gland involvement: the "complete" form, especially in young patients, with diffuse involvement of the parathyroid glands, and the subtotal parathyroidy is the best choice, and the "incomplete" form, especially in elderly, with the involvement of a single parathyroid gland; in this way, the resection of the adenoma associated with biopsy from the other parathyroid gland is the best approach.
  • [MeSH-major] Adenoma / surgery. Gastrinoma / surgery. Insulinoma / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery. Parathyroid Neoplasms / surgery. Parathyroidectomy
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. Hyperparathyroidism, Secondary / diagnosis. Hyperparathyroidism, Secondary / etiology. Male. Middle Aged. Multiple Endocrine Neoplasia / surgery. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / surgery. Prolactinoma / diagnosis. Prolactinoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495355.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


12. van den Bergh AC, van den Berg G, Schoorl MA, Sluiter WJ, van der Vliet AM, Hoving EW, Szabó BG, Langendijk JA, Wolffenbuttel BH, Dullaart RP: Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys; 2007 Mar 1;67(3):863-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy.
  • PURPOSE: To demonstrate the benefit of immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma (NFA) in perspective to the need for hormonal substitution and life expectancy.
  • CONCLUSIONS: Immediate postoperative radiotherapy provides a marked improvement of local control among patients with residual NFA compared with surgery alone, without an additional deleterious effect on pituitary function and life expectancy.
  • [MeSH-major] Adenoma / radiotherapy. Life Expectancy. Pituitary Gland / radiation effects. Pituitary Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197121.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ergungor F, Daglioglu E, Akdemir G, Okay O, Dalgic A, Hatipoglu G: Delayed chiasmal herniation after transsphenoidal removal of a pituitary adenoma - case report. Neurol Neurochir Pol; 2008 Jan-Feb;42(1):60-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed chiasmal herniation after transsphenoidal removal of a pituitary adenoma - case report.
  • We report a 41-year-old woman who experienced visual deterioration after successful removal of a pituitary adenoma.
  • Possible mechanisms of this visual deterioration and contribution of chiasmal herniation into the sella as well as defect in the diaphragma sellae are discussed with emphasis on the regulation of medical treatment for pituitary adenomas.
  • We conclude that medical therapy after pituitary surgery should be carefully managed together with periodic visual examinations.
  • [MeSH-major] Encephalocele / etiology. Hypophysectomy / adverse effects. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365965.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Unlu A, Meco C, Ugur HC, Comert A, Ozdemir M, Elhan A: Endoscopic anatomy of sphenoid sinus for pituitary surgery. Clin Anat; 2008 Oct;21(7):627-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic anatomy of sphenoid sinus for pituitary surgery.
  • This study aimed to highlight surgical landmarks and their anatomical relationships for pituitary surgery through endoscopic perspective.
  • The width of the pituitary, which is the distance between the medial margins of the carotid prominences, was measured as 21 +/- 2.5 mm and the distance between the medial margin of the carotid prominences at the lower margin of the pituitary was 18 +/- 3.1 mm.
  • The width of the pituitary, which is the distance between the medial margins of the anterior curvature of the ICA, was measured as 23.2 +/- 3 mm, while the distance between the posterior curvature of the ICA was 19.7 +/- 4.9 mm.
  • Endoscopic view provided superior detailed visualization of the close relationships between pituitary gland, internal carotid arteries, and optic nerves.
  • [MeSH-major] Endoscopy / methods. Neurosurgical Procedures / methods. Pituitary Gland / surgery. Sphenoid Sinus / anatomy & histology
  • [MeSH-minor] Adenoma / surgery. Adult. Aged. Carotid Arteries / anatomy & histology. Humans. Male. Middle Aged. Optic Nerve / anatomy & histology. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18816443.001).
  • [ISSN] 1098-2353
  • [Journal-full-title] Clinical anatomy (New York, N.Y.)
  • [ISO-abbreviation] Clin Anat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Yasuda M, Akiyama N, Miyamoto S, Warabi M, Takahama Y, Kitamura M, Yakushiji F, Kinoshita H: Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma. Pituitary; 2010;13(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoma is one of the causative factors of hypothalamus-pituitary dysfunction, and intravascular large B-cell lymphoma (IVLBCL) is a subtype of primary extranodal neoplasm.
  • We diagnosed her with presumable non-functional primary pituitary adenoma and subsequent dysfunction.
  • Though we conducted systemic investigations including chest and abdomen enhanced computer tomography, transbronchial lung biopsy, and bone marrow biopsy, the diagnosis was not confirmed.
  • In affected sites, both sellar and pituitary stalk (6.7%), both hypothalamus and pituitary stalk (6.7%), only sellar (63.3%), only pituitary stalk (6.7%), only hypothalamus (13.3%), and only clivus (3.3%) were observed.
  • In hypothalamus-pituitary dysfunction, both anterior and posterior dysfunction (20.7%), only anterior dysfunction (58.6%), only posterior dysfunction (3.4%), and no dysfunction (17.2%) were observed.
  • It seemed that hypothalamic lesion is related to both anterior and posterior dysfunction, while sellar lesion is related to mainly anterior dysfunction.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cranial Nerves / physiology. Cranial Nerves / physiopathology. Female. Humans. Neoplasms, Second Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Acta Neuropathol. 1999 Mar;97(3):311-6 [10090680.001]
  • [Cites] Endocr J. 2005 Oct;52(5):543-9 [16284431.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):112-23 [2420221.001]
  • [Cites] Am J Med. 1999 Aug;107(2):169-76 [10460050.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3168-73 [17577023.001]
  • [Cites] Acta Neurochir (Wien). 2008 Aug;150(8):833-6 [18574548.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1470-6 [11297569.001]
  • [Cites] Pituitary. 2011 Jun;14 (2):194-7 [19123039.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1525-7 [18053461.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi [10207686.001]
  • [Cites] Australas Radiol. 2000 Feb;44(1):112-4 [10761271.001]
  • [Cites] Am J Clin Pathol. 1979 Jun;71(6):724-7 [377944.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):46-9 [19229666.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] Pituitary. 2009;12(1):76-9 [18205050.001]
  • [Cites] Am J Med. 1996 Nov;101(5):563-4 [8948282.001]
  • [Cites] Endocr Pract. 2003 Jul-Aug;9(4):296-300 [14561574.001]
  • [Cites] Wien Klin Wochenschr. 2006 Jul;118(13-14):422-5 [16865648.001]
  • [Cites] Am J Med Sci. 2004 Aug;328(2):124-8 [15311173.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):231-2 [10706771.001]
  • [Cites] Histopathology. 1997 Aug;31(2):161-6 [9279568.001]
  • [Cites] Pituitary. 2000 May;2(4):283-7 [11081150.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):335-341 [12114795.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):236-44 [18081700.001]
  • [Cites] J R Soc Med. 1997 May;90(5):274-5 [9204025.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):236-9 [15224358.001]
  • [Cites] Folia Neuropathol. 2007;45(3):144-8 [17849366.001]
  • [Cites] Rinsho Shinkeigaku. 1999 Nov;39(11):1160-3 [10689943.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2000 Jan;38(1):34-8 [10723949.001]
  • [Cites] No To Shinkei. 1998 Dec;50(12):1133-41 [9989361.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):88-91 [8225384.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):861-8 [8078533.001]
  • [Cites] Dermatology. 2004;209(2):135-7 [15316168.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):130-3 [11216706.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):246-50 [12480233.001]
  • [Cites] No Shinkei Geka. 1998 Jan;26(1):53-8 [9488992.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1611-6 [15370213.001]
  • [Cites] Medicine (Baltimore). 1999 Jul;78(4):236-69 [10424206.001]
  • [Cites] Med Pediatr Oncol. 2001 Mar;36(3):392-5 [11241445.001]
  • [Cites] Cas Lek Cesk. 2008;147(11):569-73 [19097361.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1738-45 [8156502.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):227-31 [15072472.001]
  • [Cites] Blood. 2007 Jan 15;109(2):478-85 [16985183.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3189-95 [18506023.001]
  • [Cites] Endocrine. 2008 Aug-Dec;34(1-3):11-6 [18937075.001]
  • [Cites] J Clin Neurosci. 2008 Oct;15(10):1148-51 [18653342.001]
  • (PMID = 19707877.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


16. Pollock BE, Jacob JT, Brown PD, Nippoldt TB: Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg; 2007 May;106(5):833-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.
  • METHODS: Retrospective analysis was performed for 46 consecutive cases of growth hormone (GH)-producing pituitary adenomas treated by radiosurgery between 1991 and 2004.
  • Biochemical remission was defined as a fasting GH less than 2 ng/ml and a normal age- and sex-adjusted insulin-like growth factor-I (IGF-I) level while patients were not receiving any pituitary suppressive medications.
  • Multivariate analysis showed that IGF-I levels less than 2.25 times the upper limit of normal (hazard ratio [HR] 2.9, 95% confidence interval [CI] 1.2-6.9, p = 0.02) and the absence of pituitary suppressive medications at the time of radiosurgery (HR 4.2, 95% CI 1.4-13.2, p = 0.01) correlated with biochemical remission.
  • The incidence of new anterior pituitary deficits was 10% at 2 years and 33% at 5 years.
  • CONCLUSIONS: Discontinuation of pituitary suppressive medications at least 1 month before radiosurgery significantly improved endocrine outcomes for patients with acromegaly.
  • Patients with GH-producing pituitary adenomas should not undergo further radiation therapy or surgery for at least 5 years after radiosurgery because GH and IGF-I levels continue to normalize over that interval.
  • [MeSH-major] Acromegaly / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Human Growth Hormone / blood. Pituitary Neoplasms / surgery. Postoperative Complications / diagnosis. Radiosurgery
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Hypopituitarism / blood. Hypopituitarism / diagnosis. Insulin-Like Growth Factor I / metabolism. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542527.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


17. Dreijerink KM, van Beek AP, Lentjes EG, Post JG, van der Luijt RB, Canninga-van Dijk MR, Lips CJ: Acromegaly in a multiple endocrine neoplasia type 1 (MEN1) family with low penetrance of the disease. Eur J Endocrinol; 2005 Dec;153(6):741-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome that is characterised by the occurrence of tumours in the parathyroid glands, the endocrine pancreas, the pituitary gland and the adrenal glands and by neuroendocrine carcinoid tumours, often at a young age.
  • We present a patient with a history of parathyroid adenomas also showing signs of acromegaly.


18. Wu ZB, Su ZP, Wu JS: Spontaneous remission of pituitary macroadenomas in women: report of two cases. Chin Med J (Engl); 2007 Nov 20;120(22):2062-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of pituitary macroadenomas in women: report of two cases.
  • [MeSH-major] Adenoma / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067800.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Estrogens; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


19. Stranjalis G, Stavrinou LC, Kouyialis AT, Sakas DE: A modified speculum for transsphenoidal surgery: technical note. Neurosurg Rev; 2009 Oct;32(4):491-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This technical note presents the advantages of a modified nasal speculum for the translabial-endonasal transsphenoidal approach to the sphenoid sinus and sella for surgery on lesions of the pituitary.
  • We performed 50 transsphenoidal procedures for pituitary adenomas using the remodeled speculum.
  • In conclusion, the more open translabial-transnasal speculum described here definitely facilitates the transsphenoidal approach to the pituitary.
  • [MeSH-major] Adenoma / surgery. Neurosurgical Procedures / instrumentation. Pituitary Gland / surgery. Pituitary Neoplasms / surgery. Sphenoid Bone / surgery. Surgical Instruments

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Feb;92(2):359-60 [10659028.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(9):1055-8 [11086816.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):189-92; discussion 192-3 [8805160.001]
  • [Cites] J Neurosurg. 1985 Feb;62(2):307-9 [3968572.001]
  • [Cites] Neurosurgery. 2003 Apr;52(4):914-25; discussion 925-6 [12657189.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(12):1416-25 [9030348.001]
  • [Cites] Neurosurg Clin N Am. 2001 Jan;12(1):37-44, vii-viii [11175987.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):140-2 [3783248.001]
  • [Cites] J Neurosurg. 1965 Dec;23(6):612-9 [5861144.001]
  • [Cites] Neurosurgery. 1999 Aug;45(2):392-5; discussion 395-6 [10449087.001]
  • [Cites] J Neurosurg. 1975 Jan;42(1):108-10 [1110381.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Dec;45(4):193-200 [12494353.001]
  • [Cites] Neurosurg Focus. 2005 Dec 15;19(6):E2 [16398479.001]
  • (PMID = 19629552.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Taoda T, Hara Y, Takekoshi S, Itoh J, Teramoto A, Osamura RY, Tagawa M: Effect of mitotane on pituitary corticotrophs in clinically normal dogs. Am J Vet Res; 2006 Aug;67(8):1385-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mitotane on pituitary corticotrophs in clinically normal dogs.
  • OBJECTIVE: To evaluate the effects of mitotane administration on the function and morphology of pituitary corticotrophs in clinically normal dogs.
  • Magnetic resonance imaging (MRI) of the pituitary gland and brain was performed in mitotane treatment group dogs before and after administration of mitotane.
  • After CRH stimulation testing and MRI, dogs were euthanatized and the pituitary gland and adrenal glands were excised for gross and histologic examination.
  • Magnetic resonance imaging revealed that pituitary glands were significantly larger in treatment group dogs after administration of mitotane, compared with before administration.
  • Immunohistochemistry revealed hypertrophy of corticotrophs in pituitary glands of mitotane treatment group dogs.
  • CONCLUSIONS AND CLINICAL RELEVANCE: These findings indicate that inhibition of the adrenal cortex by continuous administration of mitotane leads to functional amplification and morphologic enhancement of corticotrophs in clinically normal dogs.
  • In instances of corticotroph adenoma, hypertrophy of individual corticotrophs induced by mitotane may greatly facilitate enlargement of the pituitary gland and increases in ACTH secretion.
  • [MeSH-major] Adrenocorticotropic Hormone / metabolism. Corticotropin-Releasing Hormone / metabolism. Health. Mitotane / pharmacology. Pituitary Gland / drug effects. Pituitary Gland / metabolism

  • Hazardous Substances Data Bank. MITOTANE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16881851.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


21. Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L: Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab; 2008 Jul;93(7):2746-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
  • OBJECTIVE: The aim of the study was to evaluate the Ki-67 index prognostic relevance in a group of acromegalic patients who underwent transsphenoidal surgery for a GH-secreting pituitary adenoma.
  • The Ki-67 index was determined by immunohistochemistry on tissue samples obtained from each adenoma after surgery.
  • Periodical pituitary magnetic resonance imaging and hormonal evaluation were performed during the follow-up.
  • Pituitary magnetic resonance imaging showed residual/recurrent disease in 25 of 68 patients after 6 months.
  • We suggest routine Ki-67 evaluation in GH-secreting pituitary adenomas.
  • [MeSH-major] Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / pathology. Ki-67 Antigen / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460561.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 51110-01-1 / Somatostatin
  •  go-up   go-down


22. Tsuchiya K, Ohta K, Yoshimoto T, Doi M, Izumiyama H, Hirata Y: A Case of acromegaly associated with subclinical Cushing's disease. Endocr J; 2006 Oct;53(5):679-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging of the brain revealed the presence of a pituitary macroadenoma.
  • Endocrine examination of the hypothalamo-pituitary-adrenal (HPA) axis showed a lack of circadian rhythm of ACTH and cortisol, non-suppressibility to low-dose (1 mg), but suppressibility to high-dose (8 mg) dexamethasone, and normal response to CRH stimulation.
  • The tumor resected by transsphenoidal surgery was histopathologically consistent with the diagnosis of eosinophilic adenoma: positive immunoreactivities of GH, PRL and ACTH were demonstrated, but negative immunoreactivities of prohormone convertase (PC) 1/3 by immunohistochemical method.
  • Metabolic co-morbidities such as diabetes and hypertension disappeared after removal of the pituitary tumor.
  • This is a very rare case of GH-producing pituitary adenoma causing typical acromegaly with concomitant production of ACTH causing subclinical Cushing's disease.
  • [MeSH-major] Acromegaly / complications. Pituitary ACTH Hypersecretion / complications
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / radiography. Adenoma / surgery. Adrenocorticotropic Hormone / blood. Diabetes Mellitus, Type 2 / blood. Diabetes Mellitus, Type 2 / complications. Growth Hormone-Secreting Pituitary Adenoma / diagnosis. Growth Hormone-Secreting Pituitary Adenoma / radiography. Growth Hormone-Secreting Pituitary Adenoma / surgery. Human Growth Hormone / blood. Humans. Hydrocortisone / blood. Male. Middle Aged. Pituitary Function Tests

  • Genetic Alliance. consumer health - Acromegaly.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16926523.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


23. Menon G, Bahuleyan B, Nair S: Acute subdural hematoma after transsphenoidal surgery. J Clin Neurosci; 2009 Jan;16(1):160-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 48-year-old male who developed an acute subdural hematoma after transsphenoidal decompression of a pituitary adenoma followed by a lumbar drain to conservatively manage postoperative cerebrospinal fluid rhinorrhoea.
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Neoplasms / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


24. Keil MF, Stratakis CA: Facial metrics in children with corticotrophin-producing pituitary adenomas suggest abnormalities in midface development. J Pediatr Endocrinol Metab; 2009 Jan;22(1):47-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial metrics in children with corticotrophin-producing pituitary adenomas suggest abnormalities in midface development.
  • BACKGROUND: Tumors of the hypothalamic-pituitary unit have been linked to genetic syndromes that are associated with midfacial abnormalities.
  • AIM: We hypothesized that mutations of genes that affect the development of the face (and consequently of the anterior pituitary) may be present in children with ACTH-producing pituitary adenomas, and if this is true then facial measurements would be different from those predicted by parental features.
  • RESULTS: Significant differences were seen between the children with pituitary adenomas and their parents for vertical facial height measures: nasal length (p < 0.001), lower facial height (p < 0.03) and overall facial height (p < 0.01).
  • CONCLUSION: We conclude that some of the indices of midline craniofacial development, in particular those affecting the vertical axis, are different in children with corticotroph adenomas producing ACTH.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / pathology. Adenoma / pathology. Face / pathology. Maxillofacial Abnormalities / etiology. Maxillofacial Development / physiology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Craniofac Surg. 2003 Jan;14(1):13-28 [12544216.001]
  • [Cites] Am J Med Genet. 2002 Sep 1;111(4):388-91 [12210297.001]
  • [Cites] Horm Res. 2003;60(4):168-73 [14530604.001]
  • [Cites] Am J Phys Anthropol. 1974 Nov;41(3):423-9 [4473903.001]
  • [Cites] Am J Med Genet. 1980;7(1):47-74 [7211952.001]
  • [Cites] Am J Med Genet. 1983 Mar;14(3):557-65 [6859106.001]
  • [Cites] J Craniofac Genet Dev Biol. 1985;5(3):229-38 [4044786.001]
  • [Cites] Clin Genet. 1993 Sep;44(3):129-38 [8275570.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1498-502 [7962349.001]
  • [Cites] Am J Med Genet. 1998 Oct 2;79(4):294-304 [9781911.001]
  • [Cites] Am J Phys Anthropol. 1953 Mar;11(1):121-40 [13040508.001]
  • [Cites] Horm Metab Res. 2005 Jun;37(6):347-54 [16001326.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5134-40 [15941871.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):221-4 [16219718.001]
  • [Cites] Eur J Endocrinol. 2006 May;154(5):753-8 [16645024.001]
  • [Cites] J Endocrinol Invest. 2006 Mar;29(3):208-13 [16682832.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3316-23 [16787992.001]
  • [Cites] Genes Dev. 2006 Oct 15;20(20):2871-86 [17043312.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R73-9 [17613551.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R80-7 [17613552.001]
  • [Cites] Pediatrics. 2007 Sep;120(3):e575-86 [17698579.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2701-8 [10946868.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4556-61 [11134108.001]
  • [Cites] J Pediatr. 2001 Aug;139(2):215-9 [11487746.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):95-110 [11761437.001]
  • [Cites] Ann Med. 2002;34(3):179-91 [12173688.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • (PMID = 19344074.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00001595
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD000642; United States / Intramural NIH HHS / / ZIA HD000642-13; United States / NICHD NIH HHS / HD / Z01-HD-000642-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Germany
  • [Other-IDs] NLM/ NIHMS310299; NLM/ PMC3143028
  •  go-up   go-down


25. Sung CO, Suh YL, Lee DK: Extensive spherical amyloid deposition of pituitary adenoma presenting as pituitary apoplexy. Clin Neurol Neurosurg; 2008 Apr;110(4):424-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive spherical amyloid deposition of pituitary adenoma presenting as pituitary apoplexy.
  • [MeSH-major] Amyloidosis / pathology. Pituitary Apoplexy / pathology. Pituitary Neoplasms / pathology. Prolactinoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280642.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC: Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf); 2009 May;70(5):757-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a complete response to surgery in GH-secreting macro-adenomas can be difficult, first-line therapy with octreotide LAR can be considered as a viable alternative for most patients with acromegaly, due to its low complication rate.
  • [MeSH-minor] Adult. Aged. Female. Growth Hormone-Secreting Pituitary Adenoma / blood. Growth Hormone-Secreting Pituitary Adenoma / complications. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / surgery. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acromegaly.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Endocrinol (Oxf). 2010 Jul;73(1):134; author reply 135-6 [20039884.001]
  • (PMID = 19178516.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


27. Foppiani L, Del Monte P, Ruelle A, Bandelloni R, Quilici P, Bernasconi D: TSH-secreting adenomas: rare pituitary tumors with multifaceted clinical and biological features. J Endocrinol Invest; 2007 Jul-Aug;30(7):603-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSH-secreting adenomas: rare pituitary tumors with multifaceted clinical and biological features.
  • TSH-secreting pituitary adenomas (TSH-omas) are a rare cause of hyperthyroidism in clinical practice.
  • As their diagnosis is often delayed, these tumors are mostly diagnosed as macroadenomas, preventing an effective and radical cure and leading to serious local and systemic comorbidities.
  • Magnetic resonance imaging (MRI)/computed tomography (CT) evidenced a pituitary macroadenoma and octreoscan was positive in all patients.
  • In this case, previous treatment with amiodarone confused and delayed the correct diagnosis of TSH-oma.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis. Thyrotrophs / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Sep;54(2):179-86 [11761434.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):176-81 [15670193.001]
  • [Cites] Trends Endocrinol Metab. 1992 Mar;3(2):41-5 [18407076.001]
  • [Cites] South Med J. 2003 Sep;96(9):933-6 [14513996.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):728-31 [9211757.001]
  • [Cites] Mol Endocrinol. 2001 Sep;15(9):1529-38 [11518802.001]
  • [Cites] Am J Med. 2005 Jul;118(7):706-14 [15989900.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3084-90 [8768879.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):735-43 [12072042.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):524-8; quiz following p528 [16957766.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5572-6 [11701737.001]
  • [Cites] Pituitary. 2002;5(2):83-8 [12675505.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):708-11 [14764785.001]
  • (PMID = 17848845.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


28. Barahona MJ, Sojo L, Wägner AM, Bartumeus F, Oliver B, Cano P, Webb SM: Determinants of neurosurgical outcome in pituitary tumors. J Endocrinol Invest; 2005 Oct;28(9):787-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of neurosurgical outcome in pituitary tumors.
  • OBJECTIVE: Neurosurgery is one of the main therapies for pituitary tumors; optimising outcome is highly desirable for the patient and the health system.
  • We have analysed predictors of outcome in surgically treated pituitary adenomas operated in this centre.
  • DESIGN AND PATIENTS: A total of 289 patients underwent neurosurgery for a pituitary tumor, by the same two neurosurgeons, between 1982 and 2001.
  • CONCLUSIONS: PRL secretion, tumor size and operation date are the main predictors of neurosurgical outcome in pituitary tumors, the latter suggesting that neurosurgical experience plays an important role.
  • [MeSH-major] Adenoma / surgery. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26 [9768641.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72 [12915637.001]
  • [Cites] Pituitary. 1999 Jun;2(1):51-4 [11081172.001]
  • [Cites] J Neurosurg. 2004 Apr;100(4):634-8 [15070117.001]
  • [Cites] Eur J Endocrinol. 2002 Feb;146(2):179-86 [11834426.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jun;58(6):763-9 [12780754.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3696-700 [10523016.001]
  • [Cites] QJM. 1999 Dec;92(12):741-5 [10581337.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Nov;43(5):517-22 [8548933.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):307-14 [12186458.001]
  • [Cites] Surg Neurol. 2000 Mar;53(3):211-9 [10773251.001]
  • [Cites] QJM. 1994 Oct;87(10 ):617-23 [7987657.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Jun;44(6):711-6 [8759184.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5695-9 [11739423.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jan;58(1):86-91 [12519417.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3411-8 [9768640.001]
  • [Cites] BMJ. 1999 Sep 4;319(7210):588-9 [10473459.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 May;54(5):617-26 [11380492.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Jan;38(1):73-8 [8435888.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1131-9 [15001598.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Sep;45(3):291-8 [8949566.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1645-52 [11297598.001]
  • [Cites] BMJ. 1994 Nov 26;309(6966):1409-10 [7819849.001]
  • [Cites] J Endocrinol Invest. 2005 Jan;28(1):18-22 [15816366.001]
  • [Cites] J Neurosurg. 1998 Sep;89(3):353-8 [9724106.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 May;50(5):561-7 [10468920.001]
  • [Cites] Ann Intern Med. 1999 May 18;130(10):821-4 [10366371.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):281-4 [10469006.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4596-602 [11134114.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4709-19 [14557445.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 May;36(5):459-65 [1617796.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2647-52 [8675592.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2789-96 [15181059.001]
  • [Cites] Eur J Endocrinol. 2004 Oct;151(4):439-46 [15476442.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):254-61; discussion 261-3 [9932878.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Apr;56(4):541-51 [11966748.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):25-31 [11849243.001]
  • [Cites] Surg Neurol. 1996 Apr;45(4):341-6 [8607082.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):669-92 [1521518.001]
  • [Cites] Eur J Endocrinol. 1999 Jan;140(1):43-7 [10037250.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Nov;49(5):653-7 [10197082.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Oct;45(4):407-13 [8959078.001]
  • (PMID = 16370556.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


29. Yavasoglu I, Kucuk M, Coskun A, Guney E, Kadikoylu G, Bolaman Z: Polycystic ovary syndrome and prolactinoma association. Intern Med; 2009;48(8):611-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperprolactinemia is the most common pituitary hormone hypersecretion syndrome in both men and women.
  • Pituitary MRI showed 6x8 mm microadenoma at left half.
  • After six months of bromocriptine treatment her prolactin level was normal and no adenoma was detected in pituitary MRI.
  • [MeSH-major] Bromocriptine / therapeutic use. Pituitary Neoplasms / complications. Polycystic Ovary Syndrome / complications. Prolactinoma / complications

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367058.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hormone Antagonists; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


30. van der Hoek J, Lamberts SW, Hofland LJ: The somatostatin receptor subtype 5 in neuroendocrine tumours. Expert Opin Investig Drugs; 2010 Mar;19(3):385-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The somatostatin receptor subtype 5 in neuroendocrine tumours.
  • IMPORTANCE OF THE FIELD: In recent years, scientific work has been intensified to unravel new (patho-) physiological insights, particularly regarding the functional role of somatostatin (SRIF) receptor subtype 5 (sst) and the development of novel sst(5)-targeted SRIF analogues, in order to broaden medical therapeutic opportunities in patients suffering from neuroendocrine diseases.
  • AREAS COVERED IN THIS REVIEW: The scope of this review is primarily focused upon recent insights in sst(5)-receptor physiology, novel sst(5)-targeted treatment options predominantly directed towards pituitary adenomas, and gastroenteropancreatic neuroendocrine tumours.
  • The sst(5) subtype might function as sst(2) modulator in terms of receptor internalization and desensitization, and seems less important compared with sst(2)-preferring SRIF analogues in the regulation of human insulin secretion by the pancreas.
  • Finally, absence of sst(5) in corticotroph adenomas could be related to tumour aggressiveness in Cushing's disease.
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / physiopathology. Animals. Drug Design. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / physiopathology. Humans. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / physiopathology. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20151855.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 0 / somatostatin receptor 5
  • [Number-of-references] 101
  •  go-up   go-down


31. Wasko R, Jaskula M, Kotwicka M, Andrusiewicz M, Jankowska A, Liebert W, Sowinski J: The expression of ghrelin in somatotroph and other types of pituitary adenomas. Neuro Endocrinol Lett; 2008 Dec;29(6):929-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of ghrelin in somatotroph and other types of pituitary adenomas.
  • OBJECTIVES: It has been suggested that ghrelin synthesized locally in pituitary regulates the function and growth of pituitary cells in autocrine/paracrine way and might be an important factor of pituitary tumorogenesis.
  • The expression of ghrelin receptor in neoplastic cells of pituitary adenomas has also been demonstrated.
  • The presence of both ghrelin mRNA and protein was detected in a number of benign and malignant neoplasms as well as in neoplastic cells of the tissues which do not express ghrelin in physiological conditions.
  • This study showed the presence of ghrelin mRNA and its protein in different types of pituitary adenomas.
  • DESIGN: The samples of 37 pituitary adenomas were obtained during standard neurosurgical tumor removal.
  • The study tissues included 20 somatotroph tumors (15 patients treated and 5 patients untreated with octreotide LAR before the surgery), 12 nonfunctioning adenomas, 4 prolactinomas and 1 ACTH-secreting tumor.
  • Expression of ghrelin mRNA was studied in 28 pituitary adenomas by RT-PCR.
  • RESULTS: The presence of ghrelin gene transcripts was demonstrated in 10 out of 15 examined somatotroph tumors (obtained from patients treated with octreotide LAR before the surgery) and also in 2 out of 4 samples of prolactinomas, 7 out of 8 of nonfunctioning tumors and in 2 samples of normal pituitary.
  • CONCLUSIONS: The study demonstrated that ghrelin gene is expressed in somatotroph adenomas, both treated and untreated with octreotide LAR before the surgery, and also in other types of pituitary adenomas (prolactinomas and nonfunctioning adenomas).
  • [MeSH-major] Adenoma / metabolism. Ghrelin / metabolism. Pituitary Neoplasms / metabolism. Somatotrophs / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112387.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Ghrelin; 0 / RNA, Messenger
  •  go-up   go-down


32. Pickett CA: Update on the medical management of pituitary adenomas. Curr Neurol Neurosci Rep; 2005 May;5(3):178-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the medical management of pituitary adenomas.
  • The medical treatment of pituitary adenomas has changed significantly over the past decade.
  • Pharmacologic therapy for prolactinomas in the form of dopamine agonists has been available since the 1970s, and somatostatin analogues for treatment of growth hormone (GH)-secreting adenomas were introduced in the 1980s.
  • Furthermore, long-acting somatostatin analogues also have utility in treating thyrotropin adenomas and a subset of adrenocorticotroph tumors.
  • Limited clinical studies with long-acting dopamine agonists suggest that a subset of patients with GH, adrenocorticotroph, and gonadotropin/nonsecreting adenomas may also benefit from therapy with these agents.
  • This article highlights some of these evolving new ideas and approaches to the pharmacologic management of pituitary adenomas.
  • [MeSH-major] Adenoma / drug therapy. Dopamine Agonists / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neth J Med. 2001 Dec;59(6):286-91 [11744180.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):495-500 [14764751.001]
  • [Cites] Pituitary. 2001 Aug;4(3):173-8 [12138990.001]
  • [Cites] Lancet. 2001 Nov 24;358(9295):1754-9 [11734231.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1381-8 [12727930.001]
  • [Cites] Endocr Rev. 2002 Oct;23 (5):623-46 [12372843.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Sep;10 (9):1725-35 [11772281.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):223-40, viii [10207693.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] Horm Res. 2003;60(2):53-60 [12876414.001]
  • [Cites] Trends Endocrinol Metab. 2001 Nov;12 (9):408-13 [11595543.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):19-21 [11849241.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2958-61 [10946911.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1222-6 [15001614.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 3):2S19-24 [12037499.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2452-62 [15126577.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3099-102 [15240576.001]
  • [Cites] Drugs. 2004;64(16):1817-38 [15301564.001]
  • [Cites] Horm Res. 2004;62 Suppl 3:79-92 [15539805.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71 [11849248.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 May;54(5):617-26 [11380492.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1131-9 [15001598.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):658-61 [14764777.001]
  • [Cites] Horm Res. 2000;53 Suppl 3:76-87 [10971110.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7 [12107214.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10 ):4759-67 [14557452.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Oct;5(10 ):1072-9 [15535428.001]
  • [Cites] Eur J Endocrinol. 2004 Aug;151(2):173-8 [15296471.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):281-4 [10469006.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45 [10762286.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):147-66 [12690986.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4709-19 [14557445.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Endocr Relat Cancer. 2001 Dec;8(4):287-305 [11733226.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3537-42 [12161471.001]
  • [Cites] Eur J Nucl Med. 1999 Jan;26(1):46-50 [9933661.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):81-7 [12690980.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:57-61 [15477719.001]
  • [Cites] Pituitary. 2002;5(2):77-82 [12675504.001]
  • [Cites] Horm Res. 2004;62 Suppl 3:74-8 [15539804.001]
  • [Cites] Pituitary. 1999;1(2):115-20 [11081189.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):25-31 [11849243.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1171-7 [10770982.001]
  • [Cites] J Endocrinol Invest. 2004 May;27(5):RC8-11 [15279069.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):209-15 [15272916.001]
  • (PMID = 15865883.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Receptors, Somatotropin; 51110-01-1 / Somatostatin; 9002-72-6 / Growth Hormone
  • [Number-of-references] 50
  •  go-up   go-down


33. Saunders S, Vora JP: Endocrine evaluation of pituitary tumours. Br J Neurosurg; 2008 Aug;22(4):602-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine evaluation of pituitary tumours.
  • This paper aims to provide a framework for understanding the investigations and management of pituitary adenomas from an endocrinologists viewpoint.
  • [MeSH-major] Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Acromegaly / diagnosis. Adrenocorticotropic Hormone / metabolism. Cushing Syndrome / diagnosis. Endocrinology / education. Growth Hormone / secretion. Humans. Paraneoplastic Endocrine Syndromes / diagnosis. Practice Guidelines as Topic. Prolactinoma / diagnosis. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803082.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


34. Zhang X, Zhou Y, Klibanski A: Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):40-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.
  • Recently, progress has been made in understanding human pituitary tumor pathogenesis by the investigation of differences in gene expression between normal pituitary tissue and pituitary tumors.
  • A number of approaches, including differential display (DD), representational difference analysis (RDA), and microarray analysis have been used and several molecular targets potentially associated with pituitary tumor development and invasion have been identified.
  • We have used RDA to compare gene expression patterns between normal human pituitary and clinically non-functioning pituitary adenomas, and identified genes with growth suppression function which are expressed in the normal pituitary but not in pituitary tumors.
  • In particular, we have focused on an imprinted gene, Maternally Expressed Gene 3 (MEG3), which is specifically associated with clinically non-functioning pituitary adenomas of a gonadotroph lineage.
  • Therefore, these studies have revealed novel mechanisms for the function of a non-coding RNA in pituitary physiology and tumorigenesis.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Endocr Pathol. 2007 Summer;18(2):76-8 [17916996.001]
  • [Cites] Methods Mol Med. 2007;135:77-90 [17951653.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20926-31 [18087038.001]
  • [Cites] Pituitary. 2008;11(1):71-5 [18058237.001]
  • [Cites] Endocrinology. 2008 Mar;149(3):1235-42 [18079202.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):1984-96 [18381936.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12417-22 [18719115.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25 [18628527.001]
  • [Cites] Nat Genet. 2008 Nov;40(11):1329-34 [18836444.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Apr;24(4):328-36 [10092131.001]
  • [Cites] Methods Enzymol. 1999;303:325-49 [10349653.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):143-51 [15994756.001]
  • [Cites] Endocrine. 2005 Oct;28(1):27-35 [16311407.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1852-61 [16288219.001]
  • [Cites] Neuroendocrinology. 2005;82(3-4):208-14 [16601360.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Endocrine. 2006 Jun;29(3):435-44 [16943582.001]
  • [Cites] Pituitary. 2006;9(4):317-21 [17082898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4101-5 [17360484.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1618-28 [17456767.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1891-6 [17244780.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1952-5 [17299063.001]
  • [Cites] Endocr Relat Cancer. 2008 Dec;15(4):905-15 [18780796.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1891-9 [19034281.001]
  • [Cites] Annu Rev Pathol. 2009;4:97-126 [19400692.001]
  • [Cites] Mol Biol Cell. 2009 Jul;20(14):3353-62 [19477929.001]
  • [Cites] Cancer Res. 2009 Dec 15;69(24):9271-80 [19934310.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Bone. 1999 Jul;25(1):119-22 [10423035.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):490-7 [10404060.001]
  • [Cites] J Pathol. 1999 Jun;188(2):168-73 [10398160.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2179-86 [15644399.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1574-80 [15798773.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1211-6 [10728677.001]
  • [Cites] Genes Cells. 2000 Mar;5(3):211-20 [10759892.001]
  • [Cites] Genome Res. 2000 Nov;10(11):1711-8 [11076856.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):591-6 [11120891.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3097-107 [11443173.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):77-86 [11773001.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1262-7 [11889197.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):462-70 [12403781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1034-9 [12552124.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4218-24 [12874029.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):97-102 [12937418.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5119-26 [14602737.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):936-44 [14647444.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1827-39 [15105437.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Nature. 1989 Nov 16;342(6247):281-5 [2812027.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):336-40 [1973174.001]
  • [Cites] Cell. 1991 Feb 22;64(4):849-59 [1997210.001]
  • [Cites] Nature. 1991 May 9;351(6322):153-5 [1709450.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Apr;74(4):914-9 [1312542.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jun;74(6):1343-51 [1375599.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1303-9 [1358909.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1089-94 [8496297.001]
  • [Cites] Cell. 1993 May 21;73(4):725-34 [8500166.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):50-5 [8100831.001]
  • [Cites] Nature. 1993 Oct 21;365(6448):764-7 [7692308.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):387-92 [8106627.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):253-7 [8027238.001]
  • [Cites] Oncogene. 1994 Oct;9(10):3063-5 [7916149.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):809-14 [7889618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2159-63 [7534414.001]
  • [Cites] Oncogene. 1995 Mar 16;10(6):1193-8 [7700644.001]
  • [Cites] Methods Enzymol. 1995;254:304-21 [8531695.001]
  • [Cites] Trends Genet. 1995 Aug;11(8):303-7 [8585127.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2493-6 [8653683.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Mol Carcinog. 1997 Aug;19(4):221-4 [9290697.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5446-51 [9407947.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1388-91 [9543172.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2187-93 [9811450.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):370-7 [17111382.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5126-9 [17018653.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):356-65 [17200207.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):967-75 [17138656.001]
  • [Cites] Methods Mol Biol. 2007;353:265-300 [17332646.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):24731-42 [17569660.001]
  • (PMID = 20211686.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK040947-15A1; United States / NIDDK NIH HHS / DK / R01 DK040947; United States / NIDDK NIH HHS / DK / R01 DK040947-15A1; United States / NIDDK NIH HHS / DK / R01DK40947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Untranslated; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS192639; NLM/ PMC2904873
  •  go-up   go-down


35. Kryzanski JT, Annino DJ, Gopal H, Heilman CB: Low complication rates of cranial and craniofacial approaches to midline anterior skull base lesions. Skull Base; 2008 Jul;18(4):229-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low complication rates of cranial and craniofacial approaches to midline anterior skull base lesions.
  • OBJECTIVE: Surgery is a cornerstone of treatment for a wide variety of neoplastic, congenital, traumatic, and inflammatory lesions involving the midline anterior skull base and may result in a significant anterior skull base defect requiring reconstruction.
  • This study is a retrospective analysis of the reconstruction techniques and complications seen in a series of 58 consecutive patients with midline anterior skull base pathology treated with craniotomy or a craniofacial approach.
  • DESIGN: This is a retrospective analysis of 58 consecutive patients who had surgery for a midline anterior skull base lesion between January 1994 and July 2003.
  • RESULTS: Twenty-nine patients underwent surgery for a meningioma (50%).
  • The remainder had frontoethmoidal cancer, mucoceles/invasive nasal polyps, encephalocele, esthesioneuroblastoma, anterior falx dermoid cyst with a nasal sinus tract, or invasive pituitary adenoma.
  • CONCLUSIONS: Transcranial approaches for midline anterior skull base lesions can be performed safely with a low incidence of postoperative CSF leak, meningitis, bone flap infection, and symptomatic pneumocephalus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1985 Oct;150(4):406-13 [4051102.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Jul;112(7):745-9 [3707737.001]
  • [Cites] Plast Reconstr Surg. 1984 Jul;74(1):10-8 [6739582.001]
  • [Cites] Laryngoscope. 1979 Jul;89(7 Pt 1):1077-91 [449551.001]
  • [Cites] Am J Surg. 1975 Oct;130(4):463-9 [1166938.001]
  • [Cites] Neurosurgery. 2004 Jul;55(1):239-44; discussion 244-6 [15214996.001]
  • [Cites] Laryngoscope. 2002 Mar;112(3):424-7 [12148847.001]
  • [Cites] Minim Invasive Neurosurg. 2001 Dec;44(4):190-3 [11830775.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):711-4 [11014555.001]
  • [Cites] J Craniomaxillofac Surg. 1999 Aug;27(4):228-34 [10626256.001]
  • [Cites] Laryngoscope. 1999 Dec;109(12):1959-66 [10591355.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jul;123(7):738-42 [9236594.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):400-6 [17367062.001]
  • [Cites] Neurosurgery. 2007 Jan;60(1):46-58; discussion 58-9 [17228252.001]
  • [Cites] Skull Base Surg. 1999;9(2):95-100 [17171124.001]
  • [Cites] Skull Base Surg. 1999;9(1):41-6 [17171080.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Jul;263(7):647-52 [16538505.001]
  • [Cites] Head Neck. 2005 Jul;27(7):575-84 [15825201.001]
  • [Cites] J Neurosurg. 2005 May;102(5):832-41 [15926706.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):124-7 [10389891.001]
  • [Cites] Head Neck. 1999 Jan;21(1):12-20 [9890346.001]
  • [Cites] J Surg Oncol. 1998 Dec;69(4):275-84 [9881946.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1002-10 [7760173.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):481-4 [7977980.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Nov;120(11):1203-8 [7917203.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Jun;110(6):539-46 [8208569.001]
  • [Cites] J Neurosurg. 1993 Nov;79(5):782-6 [8410261.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):385-93 [8457302.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Oct;107(4):564-9 [1437188.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1991;108(5):292-7 [1759745.001]
  • [Cites] Laryngoscope. 1991 Mar;101(3):240-4 [2000010.001]
  • [Cites] Acta Neurochir (Wien). 1988;92(1-4):83-92 [3270999.001]
  • [Cites] Plast Reconstr Surg. 1986 Sep;78(3):309-17 [3737755.001]
  • [Cites] Plast Reconstr Surg. 1986 Jun;77(6):905-10 [3714887.001]
  • [Cites] Am J Surg. 1980 Nov;140(5):618-24 [7435819.001]
  • (PMID = 19119338.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2467480
  • [Keywords] NOTNLM ; Anterior skull base / cerebrospinal fluid leak / complications / craniofacial approach / meningioma / skull base surgery
  •  go-up   go-down


36. Mehrazin M, Rahmat H, Yavari P: Epidemiology of primary intracranial tumors in Iran, 1978-2003. Asian Pac J Cancer Prev; 2006 Apr-Jun;7(2):283-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data abstracted from the patients' clinical records included age at the time of admission , sex, histological diagnosis and tumor location.
  • The average age of the patients at the diagnosis was 33.9 years (SD = 18.1) with a median of 34 years and a ranged from 1 to 95 years.
  • The five most common histological types in both sexes were meningioma in 892 cases (26%) followed by astrocytoma in 805 cases (23.4%), pituitary adenoma in 488 cases (14.2%), glioblasomaoma in 278 cases (5.1%) and ependymoma in 166 cases (4.8%).
  • Male predominance was observed for the astrocytoma group, craniopharyngiomas, ependymomas, glioblastomas, medulloblastomas, and pituitary adenomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839224.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


37. Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, Montanaro L, Ruggero D: Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res; 2010 Jul 15;70(14):6026-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis.
  • Here, we report that impairment in p27 IRES-mediated translation due to decreased levels of DKC1 activity markedly increases spontaneous pituitary tumorigenesis in p27 heterozygous mice.
  • Using a new bioluminescent mouse model, we monitored p27 translation in vivo and show that p27 IRES-mediated translation is reduced in the pituitary of DKC1 hypomorphic mice (DKC1(m)).
  • An analysis of human tumors identified a novel mutation of DKC1 (DKC1(S485G)) in a human pituitary adenoma.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27 [15803138.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):177-80 [9823898.001]
  • [Cites] Chromosoma. 2005 May;114(1):1-14 [15770508.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Science. 2006 May 12;312(5775):902-6 [16690864.001]
  • [Cites] J Pathol. 2006 Sep;210(1):10-8 [16841302.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15558-63 [17030811.001]
  • [Cites] Clin Genet. 2008 Feb;73(2):103-12 [18005359.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2388-91 [18077792.001]
  • [Cites] Recent Prog Horm Res. 1999;54:397-438; discussion 438-9 [10548885.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1211-6 [10728677.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):3087-99 [12464637.001]
  • [Cites] Science. 2003 Jan 10;299(5604):259-62 [12522253.001]
  • [Cites] Hum Mol Genet. 2003 Jul 15;12(14):1767-79 [12837699.001]
  • [Cites] Hum Mol Genet. 2008 Apr 1;17(7):1031-42 [18202102.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):253-67 [18354415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Nature. 2008 Dec 18;456(7224):971-5 [19011615.001]
  • [Cites] Cell. 2009 Feb 20;136(4):731-45 [19239892.001]
  • [Cites] Nat Cell Biol. 2009 Jul;11(7):903-8 [19525934.001]
  • [Cites] J Genet Genomics. 2009 Aug;36(8):447-54 [19683667.001]
  • [Cites] PLoS One. 2009;4(9):e7147 [19779612.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1410-6 [19755982.001]
  • [Cites] J Clin Invest. 2009 Nov;119(11):3189-202 [19884662.001]
  • [Cites] Nat Genet. 2010 Jan;42(1):83-8 [19966802.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):4960-7 [11438653.001]
  • [Cites] Pituitary. 2002;5(4):235-42 [14558671.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6861-70 [15254251.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10756-61 [15240872.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):169-72 [3791205.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):288-94 [1406932.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1613-6 [7712461.001]
  • [Cites] Science. 1996 Mar 29;271(5257):1861-4 [8596954.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1870-9 [8756345.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7093-8 [9054402.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • (PMID = 20587522.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL085572; United States / NHLBI NIH HHS / HL / 3R01HL085572-05S1; United States / NHLBI NIH HHS / HL / R01 HL085572-05; United States / NHLBI NIH HHS / HL / R01 HL085572-05S1; United States / NHLBI NIH HHS / HL / R01 HL085572-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Dkc1 protein, mouse; 0 / Nuclear Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ NIHMS210968; NLM/ PMC2913864
  •  go-up   go-down


38. Kelly DF: Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus; 2007;23(3):E5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / surgery. Adenoma / surgery. Neurosurgical Procedures / methods. Pituitary ACTH Hypersecretion / surgery. Sphenoid Sinus / surgery

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961026.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


39. Emery MN, Leontiou C, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M, Grossman AB: PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf); 2006 Sep;65(3):389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
  • OBJECTIVE: It has been reported that both normal pituitary and pituitary tumours express PPAR-gamma, a nuclear hormone receptor, the expression being more abundant in pituitary tumours, and that this is the basis for the reported antiproliferative effects of the thiazolidinedione, rosiglitazone, in animal models.
  • DESIGN AND MEASUREMENTS: To investigate this further, 'real-time' PCR was used to assess PPAR-gamma mRNA expression, and Western blotting and immunohistochemistry to study its protein expression, in 46 human pituitary tumours and normal pituitary tissue.
  • Cell proliferation of the GH3 pituitary cell line was assessed by [3H]-thymidine-incorporation after 48 h rosiglitazone and pioglitazone (10(-4) M- 10(-10) M) treatment alone, or rosiglitazone in combination with the PPAR-gamma antagonist GW9662.
  • RESULTS: PPAR-gamma mRNA and protein was found to be expressed in normal pituitary and was variably expressed in pituitary tumours, but were increased specifically in nonfunctioning pituitary adenomas.
  • [MeSH-major] Adenoma / chemistry. PPAR gamma / analysis. Peroxisome Proliferator-Activated Receptors / metabolism. Pituitary Neoplasms / chemistry. Thiazolidinediones / pharmacology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. PIOGLITAZONE .
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918962.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PPAR gamma; 0 / Peroxisome Proliferator-Activated Receptors; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; X4OV71U42S / pioglitazone
  •  go-up   go-down


40. Edo AE, Eregie A: Pregnancy associated with recurrent acromegaly: a case report. West Afr J Med; 2010 Mar-Apr;29(2):120-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Acromegaly is an uncommon endocrine disorder.
  • Investigations carried out included oral glucose tolerance test with serial growth hormone assays and insulin-like growth factor 1 as well as computed tomography scan and magnetic resonance imaging of the pituitary.
  • [MeSH-major] Acromegaly / pathology. Growth Hormone-Secreting Pituitary Adenoma / pathology. Human Growth Hormone / blood. Pregnancy Complications / pathology

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544639.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Hormone Antagonists; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


41. Gasińiska T, Dec R, Wichary H, Pietrasik L, Kulawik G: [The desmopressin test in the diagnosis of Cushing's disease]. Pol Arch Med Wewn; 2007 Jan-Feb;117(1-2):20-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The desmopressin test in the diagnosis of Cushing's disease].
  • INTRODUCTION: Early and precise diagnosis is necessary in successful treatment of the patients with Cushing's disease.
  • In patients in whom magnetic resonance imaging does not visualise pituitary adenoma patient selection for surgical treatment should be based on convincing results of functional tests.
  • OBJECTIVES: The diagnostic accuracy of the desmopressin test was compared with that of the CRH test and the overnight high-dose dexamethasone suppression test in the diagnosis of Cushing's disease.
  • DESIGN AND METHOD: We studied 15 patients with pituitary-dependent Cushing's disease (10 with detected microadenoma and 5 with undetected microadenoma using magnetic resonance imaging).
  • The diagnosis was confirmed during pituitary surgery.
  • A positive response to desmopressin was present in 4 of 5 patients with undetected pituitary adenoma.
  • The highest diagnostic accuracy in the diagnosis of some patients with Cushing's disease is achieved by using a desmopressin test with high-dose dexamethasone test and CRH-test.
  • [MeSH-major] Deamino Arginine Vasopressin. Pituitary ACTH Hypersecretion / diagnosis. Pituitary Neoplasms / diagnosis. Preoperative Care / methods
  • [MeSH-minor] Adenoma / diagnosis. Adrenal Cortex Neoplasms / diagnosis. Adrenocorticotropic Hormone. Adult. Corticotropin-Releasing Hormone. Dexamethasone. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642202.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; ENR1LLB0FP / Deamino Arginine Vasopressin
  •  go-up   go-down


42. Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JW, Romijn JA: Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab; 2006 Sep;91(9):3364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma.
  • OBJECTIVE: Although a reduced quality of life (QoL) has been reported after long-term cure of functioning pituitary adenomas, the effect of successful treatment of nonfunctioning pituitary macroadenoma (NFMA) on QoL has not been fully addressed.
  • [MeSH-major] Adenoma / surgery. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787991.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Guo D, Han L, Shu K, Chen J, Lei T: Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line. J Huazhong Univ Sci Technolog Med Sci; 2007 Feb;27(1):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.
  • In the current study, it was demonstrated that LRIG1-3 and EGFR mRNA was detected in human pituitary adenoma cell lines and a normal pituitary sample, with differences in the expression levels.
  • Compared to the normal pituitary samples, the expression of LRIG1-3 in HP75 cell line was lower, but the expression of EGFR in HP75 cell line was higher.
  • The ratio of EGFR/LRIG1 was increased at least 13-fold in HP75 cells compared with the normal pituitary cells, which was also the case for the ratio of EGFR/LRIG2 (14-fold increase in HP75) and EGFR/LRIG3 (11-fold increase in HP75).
  • Further studies were needed to elucidate the explicit role of LRIG genes as negative regulators of oncogenesis in human pituitary adenoma.
  • [MeSH-major] Down-Regulation. Membrane Proteins / genetics. Membrane Proteins / metabolism. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Case-Control Studies. Cell Line, Tumor. Cloning, Molecular. DNA Primers / chemistry. DNA Probes / chemistry. DNA, Complementary / genetics. Female. Gene Expression Regulation, Neoplastic. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Membrane Glycoproteins / metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Reference Standards. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 2004 May 12;332:35-43 [15145052.001]
  • [Cites] Development. 2003 Sep;130(18):4483-93 [12900463.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 29;284(5):1155-61 [11414704.001]
  • [Cites] FEBS Lett. 2002 Jun 19;521(1-3):67-71 [12067728.001]
  • [Cites] Acta Neuropathol. 2006 Mar;111(3):238-46 [16532360.001]
  • [Cites] J Endocrinol. 2004 Nov;183(2):385-94 [15531726.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1285-9 [14520461.001]
  • [Cites] Mod Pathol. 2004 Jul;17(7):772-80 [15098012.001]
  • [Cites] Acta Oncol. 2002;41(4):352-4 [12234026.001]
  • [Cites] Genomics. 2004 Jul;84(1):157-65 [15203213.001]
  • [Cites] EMBO J. 2004 Aug 18;23 (16):3270-81 [15282549.001]
  • (PMID = 17393120.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA Probes; 0 / DNA, Complementary; 0 / LRIG1 protein, human; 0 / LRIG2 protein, human; 0 / LRIG3 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


44. Takeo C, Ikeda K, Horie-Inoue K, Inoue S: Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus. Endocr J; 2009;56(1):113-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We further analyzed the time-dependent regulation of these genes using rat pituitary adenoma, MtT/S and GH3 cells, which are known to express ERalpha.
  • [MeSH-minor] Animals. Cell Line. Female. Gene Expression Profiling. Gene Expression Regulation / drug effects. Oligonucleotide Array Sequence Analysis. Organ Specificity / drug effects. Organ Specificity / genetics. Pituitary Gland / drug effects. Pituitary Gland / metabolism. Rats. Rats, Wistar. Receptors, Estrogen / genetics. Receptors, Estrogen / metabolism. Receptors, Progesterone / genetics. Signal Transduction / drug effects. Signal Transduction / genetics


45. Fox J, Woods SK, Gundakaram A, Varma SK, Huang YH, Wong KS: Index of suspicion. Pediatr Rev; 2005 Jul;26(7):263-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Index of suspicion.

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. FENTHION .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994996.001).
  • [ISSN] 1526-3347
  • [Journal-full-title] Pediatrics in review
  • [ISO-abbreviation] Pediatr Rev
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hair Preparations; 0 / Insecticides; 7S5I7G3JQL / Dexamethasone; 9002-60-2 / Adrenocorticotropic Hormone; BL0L45OVKT / Fenthion; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


46. Haboubi H, Azam I, Edavalath M, Redfern RM, Price DE, Stephens JW: Apoplexy in a corticotrophin-secreting pituitary macroadenoma: a case report and review of the literature. QJM; 2010 Aug;103(8):607-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy in a corticotrophin-secreting pituitary macroadenoma: a case report and review of the literature.
  • [MeSH-major] Adenoma / secretion. Adrenocorticotropic Hormone / secretion. Cushing Syndrome / complications. Pituitary Apoplexy / etiology. Pituitary Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085992.001).
  • [ISSN] 1460-2393
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


47. Scacchi M, Andrioli M, Carzaniga C, Vitale G, Moro M, Poggi L, Pecori Giraldi F, Fatti LM, Cavagnini F: Elastosonographic evaluation of thyroid nodules in acromegaly. Eur J Endocrinol; 2009 Oct;161(4):607-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Ultrasound-elastography (US-E) appears to be a helpful tool for the diagnosis of thyroid cancer.
  • Thus, US-E appears to be of limited value for the diagnosis of thyroid cancer in acromegaly.

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666699.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


48. Ronchi CL, Ferrante E, Rizzo E, Giavoli C, Verrua E, Bergamaschi S, Lania AG, Beck-Peccoz P, Spada A: Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients. Clin Endocrinol (Oxf); 2008 Oct;69(4):608-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients.
  • OBJECTIVE: Long-term effects of trans-naso-sphenoidal surgery (TNS) or long-acting somatostatin analogs (SSA) on the function of hypothalamic-pituitary-adrenal (HPA) axis have been poorly investigated.
  • Aim of this study was to evaluate HPA axis integrity during the follow-up in patients with GH-secreting pituitary adenomas and preserved HPA function post-TNS or prior SSA.
  • No significant correlations between HPA axis deterioration and follow-up duration, serum GH/IGF-I levels, occurrence of other pituitary deficiencies, presence of secondary empty sella, changes in tumour or residual volume were observed.
  • [MeSH-major] Acromegaly / physiopathology. Hypothalamo-Hypophyseal System / physiology. Pituitary-Adrenal System / physiology
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / metabolism. Adenoma / physiopathology. Adrenocorticotropic Hormone / blood. Adrenocorticotropic Hormone / metabolism. Adult. Aged. Basal Metabolism / physiology. Delayed-Action Preparations. Disease Progression. Female. Follow-Up Studies. Humans. Hydrocortisone / blood. Hydrocortisone / metabolism. Male. Middle Aged. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / physiopathology. Retrospective Studies. Somatostatin / administration & dosage. Somatostatin / analogs & derivatives. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410544.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


49. Kontogeorgos G, Mourouti G, Kyrodimou E, Liapi-Avgeri G, Parasi E: Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells. Acta Neuropathol; 2006 Jul;112(1):21-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells.
  • Ganglion cell containing pituitary adenomas are rare.
  • Recently accumulated information suggests a common origin for their neuronal and pituitary constituents.
  • The objective of this study was to report the clinical and morphologic findings of pituitary gangliocytomas and study their immunoprofile using neuronal markers.
  • Seven cases of pituitary gangliocytomas retrieved from 1,322 sellar lesions were studied.
  • Histologically they were biphasic composed of pituitary adenoma and clusters of ganglion cells embedded in a variably dense neuropil substrate.
  • All adenomas belonged to the category of sparsely granulated somatotroph adenoma and were positive for growth hormone, whereas in five tumors, a few adenoma cells were also positive for prolactin.
  • Interestingly, all tumors contained varying numbers of adenoma cells with NFP-positive, dot-like areas of cytoplasmic reactivity, mostly tiny paranuclear, a finding not previously reported in human pituitary gangliocytomas.
  • The presence of NFP in pituitary adenomas indicates neuronal differentiation in adenoma cells, suggesting a common origin for neuronal and pituitary adenoma cell elements in gangliocytomas.
  • [MeSH-major] Adenoma / classification. Adenoma / pathology. Ganglioneuroma / classification. Ganglioneuroma / pathology. Pituitary Neoplasms / classification. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699777.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neurofilament Proteins
  •  go-up   go-down


50. Killory BD, Kresl JJ, Wait SD, Ponce FA, Porter R, White WL: Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurgery; 2009 Feb;64(2 Suppl):A19-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results.
  • OBJECTIVE: Radiation therapy is recommended for pituitary tumors that are refractory to surgical and medical therapies.
  • METHODS: We reviewed our first 20 patients with recurrent or residual pituitary adenomas within 3 mm of the optic chiasm treated with the CyberKnife radiosurgery system (Accuray, Inc., Sunnyvale, CA).
  • CONCLUSION: This preliminary study establishes that the optic nerve and chiasm tolerate CyberKnife hypofractionated radiosurgery of 5 x 500 cGy to perichiasmatic pituitary adenomas.
  • [MeSH-major] Pituitary Neoplasms / surgery. Radiosurgery / adverse effects. Vision, Ocular / radiation effects
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Optic Chiasm / radiation effects. Optic Chiasm / surgery. Pituitary Gland / radiation effects. Retrospective Studies. Vision Tests

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165069.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Argyropoulou MI, Kiortsis DN: MRI of the hypothalamic-pituitary axis in children. Pediatr Radiol; 2005 Nov;35(11):1045-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI of the hypothalamic-pituitary axis in children.
  • In childhood, the MR characteristics of the normal pituitary gland are well established.
  • Pituitary gland height (PGH) decreases during the 1st year of life and then increases, reaching a plateau after puberty.
  • On dynamic contrast-enhanced studies, the posterior pituitary lobe enhances simultaneously with the straight sinus, and the adenohypophysis later, but within 30 s.
  • Pituitary enlargement, observed in Prop 1 gene mutations, is characterized by a mass interposed between the anterior and posterior lobes.
  • An ectopic posterior lobe (EPP), associated with a hypoplastic or absent pituitary stalk, may be observed in patients with hypopituitarism.
  • Tumors of the hypothalamic-pituitary (HP) axis may be the origin of adenohypophyseal deficiencies.
  • Absence of the posterior lobe bright signal, with or without a thick pituitary stalk or a mass at any site from the median eminence to the posterior pituitary lobe, may be found in diabetes insipidus.
  • Increased PGH in girls with idiopathic CPP is useful for its differential diagnosis from premature thelarche (PT).
  • Pituitary adenomas, observed mainly in adolescents, present the same MR characteristics as those in adults.
  • [MeSH-major] Hypothalamic Diseases / pathology. Hypothalamo-Hypophyseal System / pathology. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2001 Sep;55(3):423-6 [11589690.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1362-7 [9141516.001]
  • [Cites] Neuroradiology. 2000 Sep;42(9):648-50 [11071436.001]
  • [Cites] Pediatr Radiol. 1991;21(4):247-9 [1870916.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):1954-60 [10372693.001]
  • [Cites] Horm Res. 2000;54(2):98-100 [11251374.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2003 May;111(3):162-7 [12784190.001]
  • [Cites] Neurol India. 2004 Dec;52(4):501-3 [15626846.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):77-87 [9010523.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):764-9 [10603020.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):555-9 [10658742.001]
  • [Cites] Acta Radiol. 2001 Mar;42(2):129-34 [11259937.001]
  • [Cites] Radiology. 1987 Nov;165(2):487-9 [3659371.001]
  • [Cites] Endocrinol Metab Clin North Am. 1996 Sep;25(3):523-40 [8879985.001]
  • [Cites] J Endocrinol Invest. 2004 May;27(5):496-509 [15279086.001]
  • [Cites] AJNR Am J Neuroradiol. 1988 May-Jun;9(3):453-60 [3132820.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1567-9 [11090376.001]
  • [Cites] Neuroradiology. 2001 Dec;43(12):1056-8 [11792043.001]
  • [Cites] J Clin Neurosci. 2001 Jan;8(1):46-8 [11148078.001]
  • [Cites] Acta Paediatr Taiwan. 2001 Jul-Aug;42(4):243-7 [11550415.001]
  • [Cites] Eur J Pediatr. 1997 Aug;156(8):597-601 [9266188.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):5076-84 [12414875.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jul-Aug;14(4):827-38 [8352153.001]
  • [Cites] Neuroradiology. 2004 Dec;46(12):1031-5 [15551093.001]
  • [Cites] Neuroradiology. 2002 May;44(5):382-8 [12012121.001]
  • [Cites] Horm Res. 1996;46(4-5):165-9 [8950615.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Sep;53(3):399-400 [10971460.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):163-8 [15670191.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1324-8 [10199773.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1170-2 [1400889.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Apr;58(4):519-27 [12641637.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jul;47(1):79-85 [9302376.001]
  • [Cites] Neuroradiology. 2004 Mar;46(3):224-6 [14985886.001]
  • [Cites] Pediatrics. 1994 Mar;93(3):409-16 [8115199.001]
  • [Cites] J Pediatr. 1992 Jun;120(6):886-91 [1593348.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1079-88 [15001591.001]
  • [Cites] Eur J Endocrinol. 2003 Mar;148(3):339-41 [12611615.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):29-35 [8021781.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Aug;16(7):1413-9 [7484625.001]
  • [Cites] Eur J Pediatr. 1999 Apr;158(4):288-92 [10206125.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jan;78(1):11-6 [8288694.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):698-710 [15591534.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4649-54 [11600520.001]
  • [Cites] Pediatr Radiol. 1997 Jan;27(1):48-53 [8995168.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):685-9 [10782778.001]
  • [Cites] Neuroradiology. 2001 Apr;43(4):305-8 [11338414.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jun;46(6):691-9 [9274699.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1645-50 [10323394.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):215-8 [10207931.001]
  • [Cites] J Clin Neurosci. 2001 May;8(3):231-4 [11386796.001]
  • [Cites] Arch Dis Child. 1989 Aug;64(8):1170-6 [2782932.001]
  • [Cites] Eur J Pediatr. 1997 Oct;156(10):758-63 [9365063.001]
  • [Cites] Eur J Endocrinol. 1998 Dec;139(6):635-40 [9916870.001]
  • [Cites] Pediatr Nephrol. 2002 Dec;17(12):1063-5 [12478359.001]
  • [Cites] J Comput Assist Tomogr. 1987 Mar-Apr;11(2):214-20 [3819117.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):505-8 [2380345.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):182-6 [10835633.001]
  • [Cites] Radiology. 1991 Jun;179(3):721-4 [2027981.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2200-6 [15126542.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10 ):4832-9 [14557462.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 May;42(5):467-73 [7621564.001]
  • [Cites] J Pediatr Endocrinol Metab. 1996 Sep-Oct;9(5):545-8 [8961132.001]
  • [Cites] Horm Res. 2003;59 Suppl 1:42-54 [12566720.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):551-4 [9090422.001]
  • [Cites] N Engl J Med. 2000 Oct 5;343(14):998-1007 [11018166.001]
  • [Cites] Am J Med Genet. 1998 Nov 2;80(2):128-32 [9805128.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1031-44 [15001582.001]
  • [Cites] J Neuroendocrinol. 2004 Apr;16(4):297-302 [15089965.001]
  • [Cites] Eur J Pediatr. 1997 Sep;156(9):684-8 [9296530.001]
  • [Cites] Eur Radiol. 2002 Jul;12 (7):1829-36 [12111075.001]
  • [Cites] Acta Radiol. 1999 Jan;40(1):88-94 [9973910.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):650-6 [15546901.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2408-13 [10404812.001]
  • [Cites] Pediatr Neurol. 2004 Feb;30(2):143-5 [14984911.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Oct;18(9):1743-7 [9367326.001]
  • [Cites] Eur J Endocrinol. 2001 Oct;145(4):439-44 [11581002.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1295-9 [1414818.001]
  • [Cites] Radiology. 1994 Nov;193(2):493-9 [7972767.001]
  • [Cites] Eur J Endocrinol. 2002 Dec;147(6):755-60 [12457450.001]
  • [Cites] Radiology. 1993 Apr;187(1):1-14 [8451394.001]
  • [Cites] J Pediatr. 2003 Oct;143(4):445-50 [14571217.001]
  • (PMID = 15928924.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 81
  •  go-up   go-down


52. Chernov MF, Kawamata T, Amano K, Ono Y, Suzuki T, Nakamura R, Muragaki Y, Iseki H, Kubo O, Hori T, Takakura K: Possible role of single-voxel (1)H-MRS in differential diagnosis of suprasellar tumors. J Neurooncol; 2009 Jan;91(2):191-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible role of single-voxel (1)H-MRS in differential diagnosis of suprasellar tumors.
  • The objective of the present study was investigation of the possible role of proton magnetic resonance spectroscopy ((1)H-MRS) for differential diagnosis of suprasellar tumors.
  • There were 19 pituitary adenomas, 7 gliomas, 5 craniopharyngiomas, 3 chordomas, meningioma, hemangiopericytoma, malignant lymphoma, germinoma, Rathke cleft cyst, and hypothalamic hamartoma (one of each).
  • [MeSH-major] Diagnosis, Differential. Magnetic Resonance Spectroscopy / methods. Protons. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / metabolism
  • [MeSH-minor] Adult. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Astrocytoma / diagnosis. Chi-Square Distribution. Choline / metabolism. Craniopharyngioma / diagnosis. Creatine / metabolism. Female. Humans. Male. Middle Aged. Pituitary Neoplasms / diagnosis

  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2006 Jul;105(1):6-14 [16874886.001]
  • [Cites] Neuroradiol J. 2008 Jun 3;21(3):338-49 [24256903.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):375-84 [17058135.001]
  • [Cites] Clin Neurol Neurosurg. 2007 Feb;109(2):111-24 [17126479.001]
  • [Cites] Technol Cancer Res Treat. 2002 Feb;1(1):17-28 [12614173.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):605-17 [15497114.001]
  • [Cites] Neuro Endocrinol Lett. 2007 Oct;28(5):560-4 [17984954.001]
  • [Cites] J Neurol. 1996 Oct;243(10):706-14 [8923303.001]
  • [Cites] Eur Radiol. 2007 Jul;17(7):1651-62 [17235536.001]
  • [Cites] Acta Neurochir (Wien). 2007 Aug;149(8):759-69; discussion 769 [17594050.001]
  • [Cites] J Med Invest. 2006 Aug;53(3-4):199-203 [16953054.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • (PMID = 18825316.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


53. Miften M, Gayou O, Reitz B, Fuhrer R, Leicher B, Parda DS: IMRT planning and delivery incorporating daily dose from mega-voltage cone-beam computed tomography imaging. Med Phys; 2007 Oct;34(10):3760-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / radiotherapy. Cone-Beam Computed Tomography / methods. Pituitary Neoplasms / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiometry / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17985621.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Snead FE, Amdur RJ, Morris CG, Mendenhall WM: Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys; 2008 Jul 15;71(4):994-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of radiotherapy for pituitary adenomas.
  • PURPOSE: To evaluate long-term local control and toxicity for pituitary adenomas treated with fractionated radiotherapy (RT).
  • METHODS AND MATERIALS: The records of 100 patients with pituitary adenomas treated between 1983 and 2003 were retrospectively reviewed.
  • RESULTS: The 10-year actuarial local control rates for nonsecreting and secreting adenomas were 98% and 73%, respectively (p = 0.0015).
  • Actuarial 10-year cause-specific survival (CSS) rates were 95% and 88%, and overall survival rates were 66% and 79% for nonsecreting and secreting adenomas, respectively.
  • CONCLUSIONS: This is one of the most mature series in the literature that documents excellent results with fractionated RT for pituitary adenoma.
  • [MeSH-major] Adenoma / mortality. Adenoma / radiotherapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Pituitary Neoplasms / mortality. Pituitary Neoplasms / radiotherapy. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403133.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Jasek E, Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E, Trela F: Microvessel density and area in pituitary microadenomas. Endocr Pathol; 2009;20(4):221-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvessel density and area in pituitary microadenomas.
  • Microvessel density (MVD) and area (MVA) were assessed in 53 clinically silent pituitary microadenomas and in surrounding normal pituitary tissue using CD34 immunostaining and digital image analysis system.
  • Twenty-one microadenomas (40%) were avascular; in the others, both MVD and MVA were significantly lower than in the normal pituitary tissue.
  • In microadenomas and in normal pituitary tissue, MVD and MVA were not significantly influenced by age or sex.
  • These results suggest that pituitary adenomas at early developmental stage are either avascular or significantly less vascular than normal pituitary tissue and that differences in vascularity of pituitary adenomas associated with the variables of sex, age, clinical presentation and immunohistochemical phenotype reported in the literature can evolve with tumor growth and possibly acquire statistical significance in large macroadenomas.
  • [MeSH-major] Adenoma / blood supply. Microvessels / pathology. Pituitary Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2008 May;23 (5):601-7 [18283645.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2890-6 [15181073.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):931-44 [16954441.001]
  • [Cites] Endocr Pathol. 1997 Autumn;8(3):189-193 [12114722.001]
  • [Cites] Microsc Res Tech. 2003 Jan 1;60(1):98-106 [12500266.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):94-101 [15558070.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):175-81 [17159250.001]
  • [Cites] Virchows Arch. 1996 Jul;428(4-5):217-21 [8764929.001]
  • [Cites] Am J Pathol. 1972 Apr;67(1):109-26 [5055626.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):329-33 [9578082.001]
  • [Cites] J Histochem Cytochem. 2006 Apr;54(4):385-95 [16234507.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1090-5 [16226108.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):231-5 [12539177.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] Int J Exp Pathol. 2007 Aug;88(4):271-7 [17696908.001]
  • [Cites] Oncol Res. 2000;12(4):203-8 [11341470.001]
  • [Cites] Histopathology. 2001 Sep;39(3):310-9 [11532042.001]
  • [Cites] Fertil Steril. 2002 Sep;78(3):581-6 [12215337.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Clin Neuropathol. 1990 Sep-Oct;9(5):251-3 [2272145.001]
  • [Cites] Hum Reprod. 2003 May;18(5):1088-93 [12721189.001]
  • [Cites] Endocr Pathol. 2004 Summer;15(2):131-9 [15299199.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):115-124 [12114647.001]
  • [Cites] Neuropathology. 2009 Feb;29(1):40-4 [18673444.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):161-9 [17200351.001]
  • [Cites] Eur J Endocrinol. 2006 May;154(5):753-8 [16645024.001]
  • (PMID = 19705298.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


56. Chung TT, Evanson J, Walker D, Akker SA, Besser GM, Monson JP, Grossman AB, Drake WM: Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. Clin Endocrinol (Oxf); 2008 Jun;68(6):965-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
  • BACKGROUND: Published data suggest that growth hormone replacement (GHR) may be given safely to patients with hypopituitarism consequent upon a pituitary/peripituitary tumour.
  • However, a preponderance of patients treated with external pituitary irradiation were included.
  • OBJECTIVE: To assess the safety of GHR in nonirradiated pituitary/peripituitary tumour.
  • PATIENTS: We imaged prospectively the pituitary glands of 48 patients (18 males; mean age 51.6 years range 21-77) who had adult onset growth hormone deficiency (AO-GHD) after appropriate treatment for a pituitary/peripituitary tumour but who did not receive external pituitary irradiation.
  • Pituitary surveillance imaging was performed prior to the commencement of GHR, at 6-12 months and then yearly.
  • Three patients were judged to have an apparent increase in tumour volume and/or marker, although only one was thought to be possibly GH related--a patient with a cystic chromophobe adenoma who demonstrated a marginal increase in residual tumour volume 4 years after commencement of GHR.
  • CONCLUSION: These data add to the growing body of evidence for the safety of GHR in hypopituitary patients consequent upon pituitary/peripituitary mass lesions and represents the first reported series in a heterogeneous group of nonirradiated patients.
  • [MeSH-major] Human Growth Hormone / adverse effects. Human Growth Hormone / therapeutic use. Hypopituitarism / drug therapy. Pituitary Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031317.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


57. Ramakrishna N: The role of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas. Nat Clin Pract Endocrinol Metab; 2008 Mar;4(3):138-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212762.001).
  • [ISSN] 1745-8374
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Tan TM, Caputo C, Mehta A, Hatfield EC, Martin NM, Meeran K: Pituitary macroadenomas: are combination antiplatelet and anticoagulant therapy contraindicated? A case report. J Med Case Rep; 2007;1:74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary macroadenomas: are combination antiplatelet and anticoagulant therapy contraindicated? A case report.
  • BACKGROUND: Pituitary apoplexy is a life-threatening endocrine emergency that is caused by haemorrhage or infarction of the pituitary gland, commonly within a pituitary adenoma.
  • CASE PRESENTATION: A 57-year-old female with a known pituitary macroadenoma was treated for suspected acute coronary syndrome with aspirin, clopidogrel and full dose enoxaparin.
  • A CT scan showed haemorrhage into the pituitary macroadenoma.
  • CONCLUSION: This case illustrates the risks of anticoagulation in a patient with a known pituitary macroadenoma, and raises the issue of whether these tumours present a relative contraindication to the use of dual antiplatelet and anticoagulation in acute coronary syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Endocrinol (Copenh). 1981 Oct;98(2):171-7 [7293648.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):187-93 [7252541.001]
  • [Cites] Acta Neurochir (Wien). 1993;120(3-4):118-22 [8460561.001]
  • [Cites] Am J Med. 1977 Jul;63(1):109-15 [879188.001]
  • [Cites] Lancet. 1997 Jul 19;350(9072):182 [9250187.001]
  • [Cites] Am J Med Sci. 1997 Nov;314(5):351-3 [9365341.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Aug;51(2):181-8 [10468988.001]
  • [Cites] Circ J. 2002 Jun;66(6):567-70 [12074275.001]
  • [Cites] Heart. 2003 Jan;89(1):10 [12482780.001]
  • [Cites] Circulation. 2003 Oct 7;108(14):1682-7 [14504182.001]
  • [Cites] Pituitary. 2004;7(3):157-63 [16010459.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):217-24 [17287411.001]
  • [Cites] Neurosurgery. 1984 Mar;14(3):363-73 [6369168.001]
  • [Cites] J Neurosurg. 1983 Oct;59(4):677-9 [6886789.001]
  • [Cites] Surg Neurol. 1995 Feb;43(2):158-64; discussion 165 [7892662.001]
  • (PMID = 17761001.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2018712
  •  go-up   go-down


59. Chan LF, Storr HL, Grossman AB, Savage MO: Pediatric Cushing's syndrome: clinical features, diagnosis, and treatment. Arq Bras Endocrinol Metabol; 2007 Nov;51(8):1261-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric Cushing's syndrome: clinical features, diagnosis, and treatment.
  • [MeSH-minor] Adenoma / complications. Adolescent. Adrenal Glands / pathology. Age Factors. Body Composition / physiology. Bone Density / physiology. Carcinoma / complications. Child. Female. Growth Disorders / diagnosis. Humans. Hyperplasia / complications. Male. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / etiology. Pituitary ACTH Hypersecretion / therapy. Pituitary Neoplasms / complications

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209864.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 65
  •  go-up   go-down


60. Chen L, Wang G, Wang RG: [Endoscopic surgery in occupation lesions of the skull base]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 May;42(5):341-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 13 malignant tumors in anterior or middle cranial fossa, 8 chordoma, 5 invasive pituitary adenoma, 4 fibrous dysplasia of the sphenoid bone, 3 neurofibroma, 3 fibroangioma, 3 ossifying fibroma and 3 other lesions.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629002.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


61. Katavetin P, Cheunsuchon P, Swearingen B, Hedley-Whyte ET, Misra M, Levitsky LL: Review: Pituitary adenomas in children and adolescents. J Pediatr Endocrinol Metab; 2010 May;23(5):427-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review: Pituitary adenomas in children and adolescents.
  • Clinical manifestations and outcomes of pituitary adenomas in children are not clearly defined.
  • We retrospectively reviewed cases of pituitary adenomas in children 0-18 years treated at MassGeneral Hospital for Children over 15 years.
  • [MeSH-major] Adenoma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Female. Growth Hormone-Secreting Pituitary Adenoma / pathology. Humans. Male. Pituitary ACTH Hypersecretion / pathology. Prolactinoma / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662340.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Trulea M, Patey M, Chaufour-Higel B, Bouquigny F, Longuebray A, Rousseaux P, Pasqual C, Tabarin A, Delemer B: An unusual case of ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab; 2009 Feb;94(2):384-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] ACTH Syndrome, Ectopic / diagnosis. Adenoma / secretion. Adrenocorticotropic Hormone / secretion. Paranasal Sinus Neoplasms / secretion
  • [MeSH-minor] Humans. Male. Middle Aged. Petrosal Sinus Sampling. Pituitary Gland. Sphenoid Sinus / pathology. Sphenoid Sinus / secretion

  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193914.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


63. De Witte O, Makiese O, Wikler D, Levivier M, Vandensteene A, Pandin P, Balériaux D, Brotchi J: [Transsphenoidal approach with low field MRI for pituitary adenoma]. Neurochirurgie; 2005 Dec;51(6):577-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsphenoidal approach with low field MRI for pituitary adenoma].
  • [Transliterated title] Apport de la résonance magnétique per-opératoire à bas champs dans la chirurgie de l'adénome hypophysaire.
  • INTRODUCTION: Appropriate evaluation of resection remains one of the major difficulties of surgical treatment of pituitary adenoma.
  • Endoscopy provides useful information but may no distinguish well residual adenoma from the pituitary gland.
  • We report our experience with low field intraoperative MRI in surgical treatment of pituitary adenoma.
  • POPULATION: Intraoperative MRI (Polestar N10, 30 patients and Polestar N20, 17 patients) was performed in 45 consecutive patients undergoing surgery for pituitary adenoma.
  • RESULTS: Intraoperative images were unavailable for two patients due to small size of the neck and the pituitary glands which were not in the middle in the field of view.
  • For the others, the pituitary glands were in the field of view and the intraoperative scans could be used for comparison.
  • A control showed no residual adenoma but hemostatic tissue.
  • CONCLUSION: Low field intraoperative MRI is an excellent technique for controlling the size of pituitary adenoma resection.
  • [MeSH-major] Adenoma / diagnosis. Magnetic Resonance Imaging. Neurosurgical Procedures / methods. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16553330.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


64. Granger N, de Fornel P, Devauchelle P, Segond S, Delisle F, Rosenberg D: Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease. J Vet Intern Med; 2005 Jan-Feb;19(1):23-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease.
  • It is difficult to predict the size of pituitary corticotroph tumors in dogs with Cushing's disease (pituitary-dependent hyperadrenocorticism [PDH]) without pituitary imaging techniques.
  • The purpose of this study was to examine the relationship between plasma adrenocorticotropin hormone (ACTH) precursor concentration and pituitary size in dogs with Cushing's disease.
  • Plasma concentrations of ACTH precursors (pro-opiomelanocortin [POMC]/pro-ACTH) and pituitary tumor height/brain area were measured in 36 dogs with pituitary corticotroph adenomas of various sizes.
  • There was a correlation between tumor size (measured as the pituitary tumor height/brain area ratio [P/B]) and POMC/pro-ACTH concentration (r = .70; P < .0001).
  • Low POMC/pro-ACTH concentrations make it unlikely that a large pituitary tumor exists in dogs with PDH.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15715043.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reagent Kits, Diagnostic; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; V27W9254FZ / Cortisone
  •  go-up   go-down


65. Hori S, Hayashi N, Nomoto K, Sato H, Hayashi T, Nagai S, Nishikata M, Endo S: Cavernous sinus cavernous hemangioma largely extending into the sella turcica and mimicking pituitary adenoma: case report. Neurol Med Chir (Tokyo); 2010;50(4):330-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous sinus cavernous hemangioma largely extending into the sella turcica and mimicking pituitary adenoma: case report.
  • A 77-year-old female presented with a rare cavernous sinus cavernous hemangioma with extension to the sella turcica, neuroradiologically mimicking nonfunctioning pituitary macroadenoma.
  • The lesion was partially removed via transsphenoidal surgery, and the histological diagnosis was cavernous hemangioma.
  • [MeSH-major] Adenoma / pathology. Cavernous Sinus / pathology. Hemangioma, Cavernous, Central Nervous System / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Radiosurgery / methods. Stereotaxic Techniques. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448429.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Falchetti A, Marini F, Luzi E, Tonelli F, Brandi ML: Multiple endocrine neoplasms. Best Pract Res Clin Rheumatol; 2008 Mar;22(1):149-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEN1 is characterized by the occurrence of parathyroid, gastro-entero-pancreatic and anterior pituitary tumours, but it can include various combinations of more than 20 endocrine and non-endocrine tumours.
  • Generally, tumours in MEN1 are benign, although gastrinomas and foregut carcinoids may exhibit a malignant course.
  • [MeSH-minor] Adenoma / genetics. Adrenocortical Carcinoma / genetics. Gastrointestinal Neoplasms / genetics. Humans. Pancreatic Neoplasms / genetics. Pheochromocytoma / genetics. Pituitary Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-ret / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Best Pract Res Clin Rheumatol. 2008 Dec;22(6):III. Brandt, Maria Luisa [corrected to Brandi, Maria Luisa]
  • (PMID = 18328987.001).
  • [ISSN] 1521-6942
  • [Journal-full-title] Best practice & research. Clinical rheumatology
  • [ISO-abbreviation] Best Pract Res Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Number-of-references] 68
  •  go-up   go-down


67. Yoshida D, Nomura R, Teramoto A: Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1α, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells. J Neuroendocrinol; 2009 May;21(5):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1α, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells.
  • Previous studies have mainly focused on the role of SDF-1 and CXCR4 in modulating the hypothalamic-pituitary axis and their possible involvement in the development of pituitary adenomas.
  • An alternative SDF-1 receptor, CXCR7, has recently been identified, but it has not been studied in the context of pituitary adenomas.
  • The present study aimed to investigate the distribution and function of CXCR7 in pituitary adenomas.
  • The expression of CXCR7, normalised to β-actin, was assessed by tissue microarray analysis of 62 adenomas, including 23 growth hormone (GH)-producing adenomas, 22 nonfunctioning adenomas, seven prolactin (PRL)-producing adenomas, six adrenocorticotrophic hormone-producing adenomas and four thyroid-stimulating hormone-producing adenomas.
  • In vitro functional studies used RNA interference (RNAi) and cDNA microarray analysis to evaluate the CXCR7 signalling pathway in AtT-20 mouse pituitary adenoma cells treated with recombinant mouse SDF-1α and transfected with RNAi against Cxcr7 or control RNAi.
  • In tissue microarray analysis, prominent expression of CXCR7 was observed in GH-producing adenomas and PRL-producing adenomas, and in macroadenomas (P < 0.05).
  • [MeSH-major] Adrenocorticotropic Hormone / secretion. Chemokine CXCL12 / metabolism. Pituitary Neoplasms / metabolism. Receptors, CXCR / metabolism. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302186.001).
  • [ISSN] 1365-2826
  • [Journal-full-title] Journal of neuroendocrinology
  • [ISO-abbreviation] J. Neuroendocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / Cmkor1 protein, mouse; 0 / Receptors, CXCR; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


68. Wass J: Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. Eur J Endocrinol; 2005 May;152(5):693-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur J Endocrinol. 2005 Jan;152(1):61-6 [15762188.001]
  • (PMID = 15879353.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 11
  •  go-up   go-down


69. Popovic V: Are there alternative tests for diagnosis of acromegaly? J Endocrinol Invest; 2005;28(11 Suppl International):73-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there alternative tests for diagnosis of acromegaly?
  • Acromegaly is a disfiguring and disabling illness, in which by definition, the disorder is caused by a pituitary GH-secreting adenoma resulting in high circulating levels of GH and IGF-I.
  • The clinical features of acromegaly include those of GH and IGF-I on tissues and the effects of the pituitary tumor itself.
  • [MeSH-major] Acromegaly / diagnosis
  • [MeSH-minor] Glucose Tolerance Test. Human Growth Hormone / blood. Human Growth Hormone / secretion. Humans. Insulin-Like Growth Factor I / analysis. Pituitary Neoplasms. Thyrotropin-Releasing Hormone

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625850.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 5Y5F15120W / Thyrotropin-Releasing Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  • [Number-of-references] 11
  •  go-up   go-down


70. Giavoli C, Ferrante E, Bergamaschi S, Ronchi CL, Lania AG, Spada A, Beck-Peccoz P: An unusual case of recurrent autoimmune hypophysitis. Exp Clin Endocrinol Diabetes; 2010 May;118(5):287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune hypophysitis (AH) is an inflammatory disease that can present either as empty sella or as pituitary mass.
  • A pituitary MRI performed 2 years before for severe headache demonstrated a large sellar and suprasellar lesion.
  • Four years later, severe headache and a MRI suggestive of pituitary adenoma recurred.
  • A MRI performed 3 months later did not show any pituitary lesion and empty sella was again described.
  • This patient represents one of the few reported cases of recurrent hypophysitis and demonstrates that both pituitary enlargement and empty-sella can be seen in the same patient at different times of his history.
  • [MeSH-major] Pituitary Diseases / radiography
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Amenorrhea / etiology. Autoimmune Diseases / pathology. Empty Sella Syndrome / pathology. Female. Human Growth Hormone / therapeutic use. Humans. Hypogonadism / drug therapy. Hypopituitarism / pathology. Pituitary Neoplasms / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691013.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


71. Kaptigau WM, Ke L: Space-occupying lesions in Papua New Guinea--the CT era. P N G Med J; 2007 Mar-Jun;50(1-2):33-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was also one case each of pineal tumour, craniopharyngioma, pituitary adenoma, vestibular schwannoma and oligodendroglioma and 6 indeterminate cases.
  • CT scan was of great help in the diagnosis and localization of SOL but, unfortunately,is still not available for the majority of the Papua New Guinea population.
  • [MeSH-major] Brain Neoplasms / radiography. Spinal Cord Diseases / radiography


72. Schaaf L, Pickel J, Zinner K, Hering U, Höfler M, Goretzki PE, Spelsberg F, Raue F, von zur Mühlen A, Gerl H, Hensen J, Bartsch DK, Rothmund M, Schneyer U, Dralle H, Engelbach M, Karges W, Stalla GK, Höppner W: Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diabetes; 2007 Sep;115(8):509-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Multiple-endocrine-neoplasia-type-1 (MEN1) is an autosomal-dominant inherited disorder characterized by the combined occurrence of primary hyperparathyroidism (pHPT), gastroenteropancreatic neuroendocrine tumors (GEP), adenomas of the pituitary gland (APA), adrenal cortical tumors (ADR) and other tumors.
  • CONCLUSION: In view of the morbidity and frequency in familial cases an effective screening programme should aim at an early diagnosis of GEP particularly when truncating, especially nonsense mutations are found.


73. Li SH, Li CQ, Dong WD: [Report of a case with ectopic pituitary adenoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Jan;43(1):66-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Report of a case with ectopic pituitary adenoma].
  • [MeSH-major] Choristoma. Paranasal Sinus Diseases. Pituitary Neoplasms

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357719.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


74. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A: The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab; 2006 Nov;91(11):4482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
  • SOM230 effects on cell proliferation and ACTH release were evaluated in vitro using primary cultures of six of the 13 human corticotroph adenomas.
  • All receptor subtypes were detected by IHC, with SSTR subtype 5 having the highest IHC score in 83% (10 of 12) of the cases.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / drug therapy. Adenoma / drug therapy. Adrenocorticotropic Hormone / secretion. Cell Proliferation / drug effects. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Immunohistochemistry. In Vitro Techniques. Male. Middle Aged. Pituitary ACTH Hypersecretion / drug therapy. RNA, Messenger / metabolism. Receptors, Somatostatin / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. Corticotropin .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940446.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; 98H1T17066 / pasireotide
  •  go-up   go-down


75. Bowden SA, Sotos JF, Stratakis CA, Weil RJ: Successful treatment of an invasive growth hormone-secreting pituitary macroadenoma in an 8-year-old boy. J Pediatr Endocrinol Metab; 2007 May;20(5):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of an invasive growth hormone-secreting pituitary macroadenoma in an 8-year-old boy.
  • We describe an 8 year-old boy with growth acceleration due to an invasive growth hormone (GH)-secreting pituitary macroadenoma who was successfully treated with the somatostatin analogue octreotide prior to transsphenoidal microsurgery.
  • [MeSH-major] Adenoma / therapy. Growth Hormone-Secreting Pituitary Adenoma / therapy. Octreotide / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642426.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] RWM8CCW8GP / Octreotide
  •  go-up   go-down


76. Poggi M, Monti S, Pascucci C, Toscano V: A rare case of follicular thyroid carcinoma in a patient with thyrotropin-secreting pituitary adenoma. Am J Med Sci; 2009 Jun;337(6):462-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of follicular thyroid carcinoma in a patient with thyrotropin-secreting pituitary adenoma.
  • OBJECTIVE: To report a rare case of a thyrotropin (TSH)-secreting pituitary adenoma associated with thyroid carcinoma.
  • METHODS: We report the clinical history, imaging studies, and laboratory and pathologic data in a male patient affected by TSH-secreting pituitary adenoma and goiter; histologic evaluation revealed thyroid carcinoma.
  • The thyroid morphologic study using Doppler ultrasonography showed a gland of increased volume with multiple nodular lesions bilaterally.
  • The nuclear magnetic resonance of the pituitary gland described a microadenoma.
  • A total thyroidectomy was performed followed by neurosurgical treatment of the pituitary lesion.
  • The patient firmly refused surgical removal of the pituitary adenoma.
  • The pituitary nuclear magnetic resonance showed a stable lesion without difference in size.
  • CONCLUSION: The clinical association between thyroid carcinoma and TSH-producing adenoma is rare, with the removal of the pituitary lesion being mandatory.
  • Pituitary surgery, in this case, is impossible, showing that TSH-producing microadenoma could seldom have an indolent behavior.
  • [MeSH-major] Adenoma / complications. Pituitary Neoplasms / complications. Thyroid Neoplasms / complications. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390430.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


77. Romano A, Chibbaro S, Marsella M, Ippolito S, Benericetti E: Carotid cavernous aneurysm presenting as pituitary apoplexy. J Clin Neurosci; 2006 May;13(4):476-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carotid cavernous aneurysm presenting as pituitary apoplexy.
  • The authors report an interesting case with a ruptured internal carotid artery aneurysm that presented as a sellar haematoma mimicking radiologically a pituitary adenoma, and clinically a pituitary apoplexy.
  • Brain MRI showed a large intra- and suprasellar mass suggestive of a pituitary macroadenoma.
  • At operation, the suspected pituitary adenoma was revealed to be a sellar haematoma; the aneurysm was successfully clipped.
  • The clinical features, the management of such a case and the importance of differential diagnosis in the acute stage are emphasised and discussed along with relevant literature.
  • [MeSH-major] Carotid Artery Diseases / complications. Intracranial Aneurysm / complications. Pituitary Apoplexy / etiology

  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678729.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


78. Zhang YC, Gao J, Xin T, Zheng ZM, Teng LZ: Expression of survivin in invasive pituitary adenoma. Saudi Med J; 2008 Nov;29(11):1589-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin in invasive pituitary adenoma.
  • OBJECTIVE: To investigate the relationship between survivin expression and invasiveness of pituitary adenoma.
  • RESULTS: Survivin was expressed in 46 (69.7%) of the investigated pituitary adenomas.
  • For invasive pituitary adenoma, survivin staining was positive in 35 (89.7%), only 11 (40.7%) specimens were positive in noninvasive tumors.
  • The chi-square test demonstrated a statistically significant difference in survivin expression between invasive and noninvasive pituitary adenoma (chi2=14.309, p=0.0002).
  • CONCLUSION: Survivin was highly associated with invasive pituitary adenoma, it is likely to serve as a useful tool for confirmation of invasive pituitary adenoma and the gene could be an effective target for pituitary adenoma gene therapy.
  • [MeSH-major] Adenoma / metabolism. Microtubule-Associated Proteins / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998006.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


79. Holcomb VB, Vogel H, Hasty P: Unlike p53, p27 failed to exhibit an anti-tumor genetic interaction with Ku80. Cell Cycle; 2009 Aug;8(15):2463-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we tested for a similar anti-tumor genetic interaction between Ku80 and the cyclin kinase inhibitor, p27(Kip1) (p27) since p27 mutant mice showed elevated levels of pituitary adenoma that were exacerbated by gamma-radiation-induced DNA damage (damage repaired by Ku80).
  • [MeSH-major] Antigens, Nuclear / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. DNA-Binding Proteins / metabolism. Pituitary Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597334.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 3P30 CA054174-16S2; United States / NIA NIH HHS / AG / P01 AG17242; United States / NCI NIH HHS / CA / R01 CA76317-05A1; United States / NIEHS NIH HHS / ES / U01 ES11044
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; 0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


80. Figueiredo EG, Paiva WS, Teixeira MJ: Extremely late development of pituitary carcinoma after surgery and radiotherapy. J Neurooncol; 2009 Apr;92(2):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely late development of pituitary carcinoma after surgery and radiotherapy.
  • INTRODUCTION: Pituitary carcinomas account for 0.1 or 0.2% of pituitary tumors.
  • The authors report a rare case of a pituitary carcinoma mimicking a radio-induced meningioma.
  • CASE REPORT: Fifty-five years-old male presents a previous history of transcranial surgery in 1983 for invasive pituitary adenoma followed by whole-brain radiotherapy (5100 cGy).
  • The histological examination revealed pituitary adenoma.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma / pathology. Neoplasms, Second Primary / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Meningioma / pathology. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neurosurgical Procedures. Radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2001 Oct;55(4):549-56 [11678840.001]
  • [Cites] Henry Ford Hosp Med J. 1984;32(1):61-6 [6746304.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):352-60 [11838811.001]
  • [Cites] Neurosurg Focus. 2004 Apr 15;16(4):E7 [15191336.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1233-9; discussion 1239-40 [10807257.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Feb;76(2):529-33 [8432799.001]
  • [Cites] Br J Radiol. 2000 Jul;73(871):783-5 [11089473.001]
  • [Cites] J Endocrinol Invest. 2002 Jan;25(1):65-72 [11883868.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):255-8 [14558601.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):402-8 [12924717.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):842-6 [8157709.001]
  • [Cites] J Endocrinol Invest. 1997 Apr;20(4):230-6 [9211132.001]
  • (PMID = 19034384.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Rennert J, Doerfler A: Imaging of sellar and parasellar lesions. Clin Neurol Neurosurg; 2007 Feb;109(2):111-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differentiation among various etiologies may not always be easy, since many of these lesions may mimic the clinical, endocrinologic and radiologic presentations of pituitary adenomas.
  • The diagnosis of sellar lesions involves a multidisciplinary effort, and detailed endocrinologic, ophthalmologic and neurologic testing are essential.
  • We here provide an overview of the most relevant MRI and CT characteristics together with clinical findings of pituitary tumors, vascular, inflammatory and infectious lesions found in the sellar/parasellar region in order to propose an appropriate differential diagnosis.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Pituitary Diseases / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adenoma / diagnosis. Cranial Fossa, Posterior / pathology. Craniopharyngioma / diagnosis. Diagnosis, Differential. Humans. Hypothalamus / pathology. Pituitary Gland / pathology. Sensitivity and Specificity


82. Komatsu F, Tsugu H, Komatsu M, Sakamoto S, Oshiro S, Fukushima T, Nabeshima K, Inoue T: Clinicopathological characteristics in patients presenting with acute onset of symptoms caused by Rathke's cleft cysts. Acta Neurochir (Wien); 2010 Oct;152(10):1673-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Rathke's cleft cysts sometimes present with acute onset, and the presentation is consistent with the features of pituitary apoplexy caused by pituitary adenoma.
  • Although pituitary apoplexy due to hemorrhage, inflammation, or infection due to an underlying Rathke's cleft cyst is difficult to diagnose pre-operatively, Rathke's cleft cyst should be included in the differential diagnosis, and early surgical treatment is needed, as for pituitary apoplexy caused by pituitary adenoma.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Cysts / pathology. Neurosurgical Procedures / methods. Pituitary Apoplexy / pathology. Pituitary Gland / abnormalities. Pituitary Gland / pathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Diagnosis, Differential. Endoscopy / instrumentation. Endoscopy / methods. Female. Fever / etiology. Headache / etiology. Humans. Hypopituitarism / etiology. Male. Middle Aged. Polyuria / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495985.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


83. Kasperlik-Załuska AA, Zgliczyński W, Jeske W, Zdunowski P: ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome. Neuro Endocrinol Lett; 2005 Dec;26(6):709-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Pituitary tumours occurring in patients bilaterally adrenalectomized because of Cushing's disease (Nelson's syndrome) are frequently invasive and a complete their resection is not possible in most of them.
  • Somatostatin was injected s.c. in two patients with NS while sodium valproate and dexamethasone were administered orally for three days in three patients with NS (two with an invasive pituitary tumour and one with a localized, intrasellar adenoma).
  • Somatostatin lowered ACTH levels in both patients, more effectively in the patient with non-invasive pituitary adenoma.
  • Valproic acid decreased moderately ACTH concentration in two patients, while following dexamethasone administration a fall in ACTH levels was observed in all three patients, the most evident in the patient with a non-invasive Nelson's adenoma.

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380696.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 51110-01-1 / Somatostatin; 614OI1Z5WI / Valproic Acid; 7S5I7G3JQL / Dexamethasone; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


84. Raitila A, Georgitsi M, Karhu A, Tuppurainen K, Mäkinen MJ, Birkenkamp-Demtröder K, Salmenkivi K, Orntoft TF, Arola J, Launonen V, Vahteristo P, Aaltonen LA: No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer; 2007 Sep;14(3):901-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene were recently observed in patients with pituitary adenoma predisposition (PAP).
  • Though AIP mutation-positive individuals with prolactin-, mixed growth hormone/prolactin-, and ACTH-producing pituitary adenomas as well as non-secreting pituitary adenomas have been reported, most mutation-positive patients have had growth hormone-producing adenomas diagnosed at relatively young age.
  • Pituitary adenomas are also component tumors of some familial endocrine neoplasia syndromes such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC).
  • Genes underlying MEN1 and CNC are rarely mutated in sporadic pituitary adenomas, but more often in other lesions contributing to these two syndromes.
  • Thus far, the occurrence of somatic AIP mutations has not been studied in endocrine tumors other than pituitary adenomas.
  • Here, we have analyzed 32 pituitary adenomas and 79 other tumors of the endocrine system for somatic AIP mutations by direct sequencing.
  • However, two out of nine patients with prolactin-producing adenoma were shown to harbor a Finnish founder mutation (Q14X) with a complete loss of the wild-type allele in the tumors.
  • These results are in agreement with previous studies in that prolactin-producing adenomas are component tumors in PAP.
  • The data also support the previous finding that somatic AIP mutations are not common in pituitary adenomas and suggest that such mutations are rare in other endocrine tumors as well.
  • [MeSH-major] Adenoma / genetics. Carcinoma / genetics. Endocrine Gland Neoplasms / genetics. Mutation. Proteins / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914118.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  •  go-up   go-down


85. Kumar SS, Ayuk J, Murray RD: Current therapy and drug pipeline for the treatment of patients with acromegaly. Adv Ther; 2009 Apr;26(4):383-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The etiology is almost exclusively an underlying pituitary adenoma.
  • Moieties with selectivity for various combinations of somatostatin receptor subtype receptors have been examined, along with molecules that additionally show high affinity for the dopaminergic D2 receptor.
  • [MeSH-minor] Adenoma / complications. Combined Modality Therapy. Dopamine / analogs & derivatives. Dopamine / therapeutic use. Dopamine Agonists / therapeutic use. Drug Discovery. Drug Evaluation. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / therapeutic use. Humans. Insulin-Like Growth Factor Binding Protein 1 / blood. Insulin-Like Growth Factor Binding Protein 1 / drug effects. Pituitary Neoplasms / complications. Radiotherapy / methods. Radiotherapy / trends. Receptors, Dopamine D2 / drug effects. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444656.001).
  • [ISSN] 1865-8652
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIM 23A760; 0 / Dopamine Agonists; 0 / Insulin-Like Growth Factor Binding Protein 1; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide; VTD58H1Z2X / Dopamine
  • [Number-of-references] 93
  •  go-up   go-down


86. Guignat L, Assie G, Bertagna X, Bertherat J: [Corticotroph adenoma]. Presse Med; 2009 Jan;38(1):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Corticotroph adenoma].
  • Corticotroph adenomas cause ACTH oversecretion responsible for Cushing's disease.
  • Ninety percent of corticotroph adenomas are microadenomas, sometime not visible on MRI.
  • Cushing's disease diagnosis requires careful hormonal and imaging investigations, aiming first at the diagnosis of Cushing's syndrome and in a second step at the diagnosis of its pituitary origin.
  • The treatment of corticotroph adenoma is mainly based on pituitary surgery.
  • In case of failure of pituitary surgery, or in patients in whom surgery is not appropriate as a first line treatment, medical therapy (mainly anticortisolic drugs), pituitary radiotherapy or surgical bilateral adrenalectomy can be discussed.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / complications. Pituitary ACTH Hypersecretion / etiology. Pituitary Neoplasms / complications
  • [MeSH-minor] Adrenalectomy. Adrenocorticotropic Hormone / analysis. Chemotherapy, Adjuvant. Corticotropin-Releasing Hormone / analysis. Cushing Syndrome / diagnosis. Cushing Syndrome / etiology. Cushing Syndrome / therapy. Diagnosis, Differential. Humans. Hydrocortisone / analysis. Hydrocortisone / antagonists & inhibitors. Magnetic Resonance Imaging. Neoadjuvant Therapy. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041214.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


87. Sade B, Mohr G, Frenkiel S: Management of intra-operative cerebrospinal fluid leak in transnasal transsphenoidal pituitary microsurgery: use of post-operative lumbar drain and sellar reconstruction without fat packing. Acta Neurochir (Wien); 2006 Jan;148(1):13-8; discussion 18-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intra-operative cerebrospinal fluid leak in transnasal transsphenoidal pituitary microsurgery: use of post-operative lumbar drain and sellar reconstruction without fat packing.
  • One hundred and ten patients had adenomas (60 secreting adenomas, 48 non-functioning), 10 Rathke's cleft cysts and 9 miscellaneous lesions.
  • FINDINGS: Intra-operative leak was detected in 43 (33.3%) of 129 procedures: 38 (34.5%) of 110 adenoma related procedures and 5 (26.3%) of 19 non-adenomas.
  • Among adenomas, leak occurred in 35 (41.2%) of 85 patients with suprasellar extension (SSE) and in 3 (12%) of 25 without SSE (p = 0.007).
  • In 24 of 34 patients (70.6%) with pre-operative drain (all adenomas), saline infusion was used to mobilize SSE.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Cattle. Female. Fibrin Tissue Adhesive. Freeze Drying. Humans. Intraoperative Complications. Male. Middle Aged. Pituitary Neoplasms / surgery. Retrospective Studies

  • Genetic Alliance. consumer health - Cerebrospinal Fluid Leak.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328773.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Fibrin Tissue Adhesive
  •  go-up   go-down


88. Mariniello B, Ronconi V, Rilli S, Bernante P, Boscaro M, Mantero F, Giacchetti G: Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol; 2006 Sep;155(3):435-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND METHODS: We have performed a case-control study and studied omental adipose tissue from a total of 24 subjects (eight obese subjects, ten patients with Cushing's syndrome due to adrenal adenoma, and six normal weight controls).

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914598.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 1
  •  go-up   go-down


89. Enseñat J, Quesada JL, Aparicio J, Pàmies C, Barber X, Topczewski T, Ferrer E: [Prospective comparative study on 50 patients between microsurgical sublabial transsphenoidal approach and endoscopic endonasal transsphenoidal approach]. Neurocirugia (Astur); 2009 Aug;20(4):335-44; discussion 344-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Comparación del abordje transesfenoidal microquirúrgico frente al abordaje endonasal transesfenoidal endosócpico. Estudio prospectivo de 50 pacientes.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Hypophysectomy / methods. Microsurgery / methods. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carotid Artery Injuries / etiology. Cavernous Sinus / pathology. Cavernous Sinus / surgery. Central Nervous System Cysts / surgery. Diabetes Insipidus, Neurogenic / etiology. Female. Humans. Hypopituitarism / etiology. Male. Meningitis / etiology. Middle Aged. Neoplasm Invasiveness. Optic Nerve / pathology. Pituitary ACTH Hypersecretion / etiology. Pituitary ACTH Hypersecretion / surgery. Postoperative Complications / etiology. Prospective Studies. Vision Disorders / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688135.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S, Burman P, Wass JA, Quinton R, Grossman AB, Korbonits M: Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf); 2009 Feb;70(2):259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recently identified gene AIP can also cause familial isolated pituitary adenoma, but no other specific tumour is associated with this syndrome.
  • PATIENTS: Eighteen sporadic and three familial cases of MEN1 mutation-negative MEN1 syndrome were studied (18 pituitary adenomas, 12 hyperparathyroidism, 10 neuroendocrine tumours including 2 ACTH-secreting lesions and one adrenal nodular hyperplasia).

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18710468.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0701307; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins; 0 / aryl hydrocarbon receptor-interacting protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


91. Pamir MN, Kilic T, Ozek MM, Ozduman K, Türe U: Non-meningeal tumours of the cavernous sinus: a surgical analysis. J Clin Neurosci; 2006 Jul;13(6):626-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective analysis of 42 cases of benign non-meningeal tumours of the cavernous sinus operated on at Marmara University between April 1992 and April 2003 is presented.
  • The study cohort consisted of 13 pituitary adenomas, 11 trigeminal schwannomas, seven chordomas, three chondrosarcomas, two juvenile angiofibromas, two epidermoid tumours, one plasmacytoma, one cavernous haemangioma and one internal carotid plexus schwannoma.
  • The majority of incompletely resected tumours were pituitary adenomas and chordomas, and 95% required further treatment.
  • The best surgical results are achieved with interdural tumours of the lateral sinus wall and the worst surgical results are seen in invasive tumours such as chordomas and pituitary adenomas.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Cranial Nerve Neoplasms. Female. Follow-Up Studies. Hemangioma, Cavernous, Central Nervous System. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurilemmoma / surgery. Pituitary Neoplasms / surgery. Retrospective Studies. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860718.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


92. Das CJ, Debnath J, Javan NG, Baruah MP: A 37-year-old married woman with 3-month history of galactorrhoea and irregular menstrual cycle. Diagnosis: multiple endocrine neoplasia type 1 (MEN 1), also known as Wermer's syndrome. Ann Saudi Med; 2007 Sep-Oct;27(5):381-2, 388-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 37-year-old married woman with 3-month history of galactorrhoea and irregular menstrual cycle. Diagnosis: multiple endocrine neoplasia type 1 (MEN 1), also known as Wermer's syndrome.
  • [MeSH-major] Adenoma / diagnosis. Galactorrhea / etiology. Menstruation Disturbances / etiology. Multiple Endocrine Neoplasia Type 1 / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Hyperparathyroidism, Primary / etiology. Magnetic Resonance Imaging. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / diagnosis


93. Ogawa Y, Tominaga T: A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment. J Neurooncol; 2008 Mar;87(1):91-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment.
  • OBJECTIVE AND IMPORTANCE: Thyrotroph cell adenoma accounts for only 1% of all pituitary adenomas.
  • Atypical adenoma has an aggressive biological character, invades the surrounding structures, and grows rapidly.
  • Atypical thyrotroph cell adenoma is extremely rare.
  • Histological examination showed atypical thyrotroph cell adenoma.
  • Second transcranial surgery failed to remove residual tumor behind the pituitary stalk.
  • The tumor has been controlled for 22 months since first surgery and diagnosis.
  • CONCLUSION: Atypical thyrotroph cell adenoma has an aggressive biological character and grows rapidly.
  • [MeSH-major] Adenoma / therapy. Neoplasm Recurrence, Local / therapy. Pituitary Neoplasms / therapy. Thyrotrophs / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Sep;54(2):179-86 [11761434.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):179-88 [17047381.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):203-16 [17287410.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Feb;40(2):275-8 [7511073.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):194-200 [10930003.001]
  • [Cites] Pituitary. 1999 May;1(3-4):221-6 [11081201.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Feb;76(2):529-33 [8432799.001]
  • [Cites] Endocrine. 2005 Oct;28(1):27-35 [16311407.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] No Shinkei Geka. 2007 Jul;35(7):679-84 [17633511.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] Pituitary. 2002;5(2):83-8 [12675505.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):708-11 [14764785.001]
  • [Cites] Eur J Endocrinol. 1999 Jun;140(6):519-27 [10366408.001]
  • (PMID = 17987261.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; RWM8CCW8GP / Octreotide
  •  go-up   go-down


94. Acebes JJ, Martino J, Masuet C, Montanya E, Soler J: Early post-operative ACTH and cortisol as predictors of remission in Cushing's disease. Acta Neurochir (Wien); 2007;149(5):471-7; discussion 477-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only three study variables were predictive of persistence of Cushing's disease after surgery: the non identification of the adenoma in histology (an adenoma was found in 87% of the patients in remission, and in 20% of treatment failures, p = 0.01), the early post-operative plasma ACTH (patients in remission: 2 pmol/L (1.1-10.8 pmol/L), treatment failures: 8.2 pmol/L (1.1-12 pmol/L), p = 0.019), and the early post-operative serum cortisol (patients in remission: 128.4 nmol/L (27.6-4644 nmol/L), treatment failures: 797 nmol/L (606-1037 nmol/L), p = 0.003).
  • CONCLUSIONS: Twenty-four hours after transsesphenoidal surgery for Cushing's disease, and without glucocorticoids replacement, patients with serum cortisol concentrations higher than 585 nmol/L, and/or plasma ACTH higher than 7.55 pmol/L, and/or those in which an adenoma is not identified in the histological study, have a high risk of treatment failure.
  • [MeSH-major] Adrenocorticotropic Hormone / blood. Hydrocortisone / blood. Pituitary ACTH Hypersecretion / blood. Pituitary ACTH Hypersecretion / surgery

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17406780.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


95. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf); 2006 Aug;65(2):265-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.
  • In June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California.
  • Members of this committee consisted of invited international experts in the field, and included endocrinologists and neurosurgeons with recognized expertise in the management of prolactinomas.
  • Discussions were held that included all interested participants to the Congress and resulted in formulation of these guidelines, which represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.
  • [MeSH-major] Algorithms. Pituitary Neoplasms. Pregnancy Complications, Neoplastic. Prolactinoma
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / therapy. Adult. Child. Dopamine Agonists / therapeutic use. Female. Follow-Up Studies. Humans. Hyperprolactinemia / diagnosis. Hyperprolactinemia / etiology. Hyperprolactinemia / therapy. Male. Pregnancy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886971.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists
  •  go-up   go-down


96. End K, Gamel-Didelon K, Jung H, Tolnay M, Lüdecke D, Gratzl M, Mayerhofer A: Receptors and sites of synthesis and storage of gamma-aminobutyric acid in human pituitary glands and in growth hormone adenomas. Am J Clin Pathol; 2005 Oct;124(4):550-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receptors and sites of synthesis and storage of gamma-aminobutyric acid in human pituitary glands and in growth hormone adenomas.
  • gamma-Aminobutyric acid (GABA) is an important regulatory factor of pituitary gland function, which in addition to hypothalamic neurons, can be derived from intrapituitary sources, ie, growth hormone (GH) cells of rat and monkey.
  • We report that human pituitary glands also express 2 isoforms of the GABA-synthesizing enzyme glutamate decarboxylase (GAD 65; GAD 67), the vesicular GABA transporter (VGAT), and multiple subunits of GABA (A, B, and C) receptors.
  • It is interesting that human pituitary GH adenomas share expression of VGAT and GABA receptors with normal pituitary glands but lack GAD 65.
  • We propose that GABA, synthesized by GH cells, might act as a paracrine or autocrine regulating factor in the human pituitary gland and in human GH adenoma.
  • [MeSH-major] Adenoma / secretion. Growth Hormone / secretion. Pituitary Gland / metabolism. Pituitary Neoplasms / secretion. Receptors, GABA / biosynthesis. gamma-Aminobutyric Acid / biosynthesis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146821.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, GABA; 56-12-2 / gamma-Aminobutyric Acid; 9002-72-6 / Growth Hormone
  •  go-up   go-down


97. Kolenc D, Zarković K, Jednacak H, Ozretić D, Habek M: Sellar angiolipomas: two case reports and a review of the literature. J Neurooncol; 2008 Aug;89(1):109-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on two patients that were initially diagnosed with pituitary adenomas that were postoperatively verified as angiolipomas.
  • Sellar angiolipomas should be considered in the differential diagnosis of pituitary lesions due to the potential catastrophic bleeding during surgery.
  • Preoperative diagnosis is very difficult; however, some MRI characteristics can help make an accurate diagnosis.
  • Adequate MRI sequences should be used in the evaluation of pituitary lesions, as they can help optimize the microsurgical management.
  • [MeSH-major] Adipose Tissue / pathology. Angiolipoma / pathology. Blood Vessels / pathology. Pituitary Gland / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Sep;49(3):219-30 [11212901.001]
  • [Cites] Surg Neurol. 1981 Feb;15(2):110-3 [7245002.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):163-7 [8121553.001]
  • [Cites] J Med Assoc Thai. 1995 Nov;78(11):631-4 [8576677.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1987 Aug;50(8):1057-9 [3655813.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jan-Feb;15(1):83-5 [1987206.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):129-32 [9420085.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • (PMID = 18480966.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 9001-27-8 / Factor VIII
  • [Number-of-references] 8
  •  go-up   go-down


98. Sahli R, Christ ER, Seiler R, Kappeler A, Vajtai I: Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review. Pathol Res Pract; 2006;202(6):457-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review.
  • Silent corticotroph adenomas (SCA) are rare pituitary tumors with histologic hallmarks of corticotroph differentiation, including ACTH immunoreactivity, but lacking clinical evidence of Cushing's syndrome.
  • Histologically, all four lesions were diagnosed as SCA subtype I displaying intense immunoreactivity for ACTH.
  • With MIB-1 labeling indices of 1-3%, none of the tumors qualified as atypical adenoma.
  • Subtle morphologic evidence of corticotroph suppression in residual pituitary adjacent to tumor lends further support to literature data indicating minimal or intermittent functional activity in this tumor type.
  • [MeSH-major] Adenoma / pathology. Adrenocorticotropic Hormone / metabolism. Pituitary Gland, Anterior / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497445.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


99. de Bruin C, Feelders RA, Lamberts SW, Hofland LJ: Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev Endocr Metab Disord; 2009 Jun;10(2):91-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increasing knowledge of specific subtype expression within these tumours and the ability to target these receptor subtypes with high-affinity compounds, has driven the search for new SS- or DA-based medical therapies for the various forms of CS.
  • In Cushing's disease, corticotroph adenomas mainly express dopamine receptor subtype 2 (D(2)) and somatostatin receptor subtype 5 (sst(5)), whereas sst(2) is expressed at lower levels.
  • Activation of these receptors can inhibit ACTH-release in primary cultured corticotroph adenomas and compounds that target either sst(5) (pasireotide, or SOM230) or D(2) (cabergoline) have shown significant efficacy in subsets of patients in recent clinical studies.
  • In both normal adrenal tissue as well as in adrenal adenomas and carcinomas that cause CS, sst and DA receptor expression has been demonstrated.
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / drug therapy. Adrenocorticotropic Hormone / metabolism. Animals. Antineoplastic Agents / therapeutic use. Humans

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 1985 Nov;41(5):363-73 [2865690.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):578-87 [12750875.001]
  • [Cites] Endocrinology. 1981 Jan;108(1):281-90 [6109620.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4460-7 [11549694.001]
  • [Cites] Science. 1985 Jul 19;229(4710):277-9 [3892690.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):645-54 [15817922.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):2976-81 [11443154.001]
  • [Cites] Horm Res. 2004;62(6):300-5 [15557761.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Feb;54(2):286-91 [6274899.001]
  • [Cites] FEBS Lett. 1994 Feb 14;339(1-2):73-5 [7508871.001]
  • [Cites] Endocrinology. 1982 Feb;110(2):657-9 [6276143.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Nov;303(2):805-14 [12388667.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] Horm Metab Res. 1991 May;23(5):233-5 [1651895.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1004-12 [16028758.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E278-87 [15769796.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23 ):2457-8 [15944436.001]
  • [Cites] Endocrinology. 1984 May;114(5):1546-9 [6143656.001]
  • [Cites] Eur J Endocrinol. 1994 Feb;130(2):125-31 [8130885.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1125-7 [166089.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):479-87, xi [15850854.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):65-9 [17032724.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):4123-30 [12239124.001]
  • [Cites] Mol Endocrinol. 1995 Sep;9(9):1193-201 [7491111.001]
  • [Cites] Mol Endocrinol. 1998 Aug;12 (8):1133-9 [9717839.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:47-50 [15477717.001]
  • [Cites] Rev Med Interne. 2007 Nov;28(11):766-9 [17574308.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):705-10 [1325994.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):39-46 [17202454.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4482-8 [16940446.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2452-62 [15126577.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jan;78(1):17-9 [7904612.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):29-38 [17202453.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):258-63 [17047391.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Jun;30(6):661-6 [2574084.001]
  • [Cites] Neuroendocrinology. 1989 Jul;50(1):44-50 [2569172.001]
  • [Cites] Horm Metab Res. 2005 Dec;37(12):722-8 [16372224.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S57-63 [17413190.001]
  • [Cites] Neuroendocrinology. 2002 Jun;75(6):339-46 [12065886.001]
  • [Cites] J Endocrinol Invest. 1999 Dec;22(11):860-5 [10710275.001]
  • [Cites] Metabolism. 1975 Jul;24(7):807-15 [1138156.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):551-8 [3024822.001]
  • [Cites] Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74 [17977644.001]
  • [Cites] Acta Endocrinol (Copenh). 1989 Jun;120(6):760-6 [2543178.001]
  • [Cites] Pituitary. 2006;9(2):151-4 [16845600.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jun;68(6):850-7 [18031328.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1044-50 [16046458.001]
  • [Cites] Endocr Rev. 1988 Nov;9(4):417-36 [2905987.001]
  • [Cites] Endocrine. 2001 Apr;14(3):329-36 [11444429.001]
  • [Cites] J Intern Med. 2008 Jan;263(1):90-8 [18036161.001]
  • [Cites] J Endocrinol Invest. 1990 Mar;13(3):257-61 [1973178.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Jun;60(6):1161-5 [2860119.001]
  • [Cites] Eur J Endocrinol. 2008 Jan;158(1):91-9 [18166822.001]
  • [Cites] J Cardiovasc Pharmacol. 1989;14 Suppl 8:S29-39 [2483440.001]
  • [Cites] Endocrine. 2003 Apr;20(3):255-64 [12721505.001]
  • [Cites] Eur J Endocrinol. 1994 Jul;131(1):91-6 [8038912.001]
  • [Cites] Lancet. 1973 Sep 15;2(7829):581-4 [4125377.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:119-33 [12381547.001]
  • [Cites] Br J Pharmacol. 2003 May;139(1):109-21 [12746229.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):21-7 [16625841.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):117-23 [11231987.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5478-82 [15956075.001]
  • [Cites] Endocrinology. 1995 Nov;136(11):5224-7 [7588261.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Nov;63(5):549-59 [16268808.001]
  • [Cites] Pituitary. 2004;7(4):257-64 [16132202.001]
  • [Cites] Eur J Endocrinol. 2001 Jan;144(1):51-7 [11174837.001]
  • [Cites] J Endocrinol Invest. 1994 Feb;17(2):135-9 [8006335.001]
  • [Cites] Endocrinology. 1998 Jan;139(1):414-9 [9421441.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):980-7 [17564168.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4493-502 [15356054.001]
  • [Cites] Lancet. 2006 May 13;367(9522):1605-17 [16698415.001]
  • [Cites] Ann Endocrinol (Paris). 2006 Sep;67(4):353-6 [17072242.001]
  • [Cites] Clin Pharmacol Ther. 2005 Jul;78(1):69-80 [16003295.001]
  • [Cites] Endocr Rev. 1993 Aug;14 (4):443-58 [7693447.001]
  • [Cites] Scand J Gastroenterol Suppl. 1986;119:84-95 [2876510.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):988-91 [2565915.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85 [15070915.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] J Endocrinol Invest. 2003 Aug;26(8):710-7 [14669823.001]
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):83-5 [8769391.001]
  • [Cites] J Clin Invest. 1994 Apr;93(4):1625-30 [8163665.001]
  • [Cites] Endocr Res. 2004 Nov;30(4):931-4 [15666847.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1576-80 [2866445.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Apr;60(4):698-705 [3882737.001]
  • [Cites] Endocrinology. 1982 Apr;110(4):1147-54 [6120829.001]
  • [Cites] Endocrinology. 1995 Nov;136(11):5232-5 [7588263.001]
  • [Cites] Physiol Rev. 1998 Jan;78(1):189-225 [9457173.001]
  • [Cites] Postgrad Med J. 1996 Jan;72(843):53-4 [8746287.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Nov;67(5):1080-3 [2846625.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):2885-90 [8768846.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):371-7 [16303835.001]
  • [Cites] Pituitary. 2002;5(2):77-82 [12675504.001]
  • [Cites] Pituitary. 2002;5(3):175-80 [12812309.001]
  • [Cites] Neuroscience. 1996 Apr;71(4):1073-81 [8684611.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):495-8 [2537335.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):28-47 [12588807.001]
  • [Cites] Science. 1973 Jan 5;179(4068):77-9 [4682131.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jan;78(1):20-4 [7904613.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4955-62 [15914534.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1055-9 [15754738.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S13-21 [17413183.001]
  • [Cites] Klin Wochenschr. 1976 Feb 15;54(4):173-5 [1256005.001]
  • [Cites] J Physiol. 1991 Aug;439:37-58 [1716675.001]
  • [Cites] J Clin Endocrinol Metab. 1980 Aug;51(2):307-11 [6249835.001]
  • [Cites] Expert Opin Pharmacother. 2000 Mar;1(3):555-74 [11249538.001]
  • [Cites] Am J Med. 1994 Apr;96(4):305-12 [8166148.001]
  • (PMID = 18642088.001).
  • [ISSN] 1573-2606
  • [Journal-full-title] Reviews in endocrine & metabolic disorders
  • [ISO-abbreviation] Rev Endocr Metab Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 115
  •  go-up   go-down


100. Unger N, Petersenn S, Mann K: [Diagnosis and therapy of endocrine hypertension]. Med Klin (Munich); 2006 Mar 22;101 Suppl 1:170-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of endocrine hypertension].
  • Once the diagnosis of hypertension is established, secondary forms should be considered.
  • A unilateral adrenal adenoma has to be separated from bilateral adrenal hyperplasia.
  • Determinations of 24-h urinary epinephrine and norepinephrine levels are established diagnostic tools for the diagnosis of pheochromocytoma.
  • In conclusion, recently established biochemical methods are reliable screening parameters for the diagnosis of adrenal hypertension.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Hyperaldosteronism / diagnosis. Hypertension / etiology. Pheochromocytoma / diagnosis. Pituitary ACTH Hypersecretion / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Epinephrine / blood. Humans. Hydrocortisone / blood. Norepinephrine / blood

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16802547.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down






Advertisement